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Abstract 
Patients receiving renal replacement therapies for end-stage renal disease experience 
markedly poorer quality of life than healthy individuals. Patients undergoing peritoneal 
dialysis experience mood disorders, body image disturbance, and changes in lifestyle and 
relationships. Research has also shown that gastrointestinal symptoms are common among 
this patient group, however, the literature exploring their relation to patients’ psychosocial 
wellbeing is yet to be summarised. This narrative review will therefore discuss the relevant 
quantitative and qualitative research regarding the impacts of peritoneal dialysis on patients’ 
psychological wellbeing and quality of life, including evidence suggesting the negative role 
of GI dysfunction in these issues.  
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The Quality of Life, Psychological Wellbeing, and Gastrointestinal Health of Patients 
Receiving Peritoneal Dialysis for End-Stage Renal Disease: A Narrative Literature Review  
Chronic kidney disease (CKD) is characterised by the irreversible decline of renal 
function, which is eventually fatal unless substituted by kidney transplantation or dialysis 
therapy (Abbasi, Chertow, & Hall, 2010). Peritoneal dialysis (PD) is a home-based therapy 
for end-stage renal disease (ESRD) that offers patients advantages including lifestyle 
flexibility and autonomy in managing their condition (Ellam & Wilkie, 2015; Wuerth, et al., 
2002). Despite this, patients undergoing PD often live with great physical and psychosocial 
burden. Research has demonstrated that sleep disturbance, fatigue, and pain are common 
(Almutary, Bonner, & Douglas, 2016), as well as gastrointestinal (GI) symptoms such as 
constipation, diarrhoea, reflux, and eating dysfunction (Almutary et al., 2016; Cano et al., 
2007; Dong, Guo, Ding, Zhou, & Wu, 2014). From the patient’s perspective, PD is also 
intrusive on daily life and relationships and has psychological consequences including body 
image disturbance and impaired self-esteem (Tong et al., 2013). It is therefore unsurprising 
that depression, anxiety, and sexual dysfunction are also prevalent among this patient group 
and that they experience markedly poorer quality of life compared to healthy individuals 
(Lew & Piraino, 2005; Merkus, et al., 1999).  
Despite the vast amount of research on quality of life in CKD populations, the 
relationships between physical symptoms and psychological wellbeing among patients 
receiving PD are not well understood. This narrative review will first provide an overview of 
the physical and psychosocial effects of ESRD and PD therapy. An examination of the 
research regarding GI symptoms, dietary management, and their relation to psychological 
wellbeing and quality of life in ESRD follows, as well as a discussion of emerging evidence 
concerning the connection between brain and GI health, or the so-called mind-gut axis. 
Relevant qualitative studies exploring the lived experiences of patients receiving PD are 
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reviewed throughout. Gaps and limitations to the current literature are identified and 
suggestions for future research are made. 
Chronic Kidney Disease 
CKD is a life-limiting condition characterised by the progressive and irreversible 
decline of kidney function. It is classified into five stages according to the level of kidney 
impairment, as measured by one’s glomerular filtration rate via a blood test. Glomerular 
filtration rate is an estimate of the amount of blood that passes through the small filters of the 
kidneys, or the glomeruli, whose function is to clear the blood of waste and toxic products. In 
the final stage of CKD (Stage 5), or ESRD, patients require kidney transplantation or dialysis 
to survive (Abbasi et al., 2010). The accumulation of toxins in the progression to and during 
ESRD results in uremic syndrome or uremia, which manifests in various neural, muscular, 
endocrine, and metabolic symptoms (Meyer & Hostetter, 2007). Uremia, uremic syndrome, 
and renal failure are terms often used synonymously with ESRD. 
Peritoneal Dialysis in Australia 
In the last two decades in Australia, the number of individuals receiving renal 
replacement therapies for ESRD has steadily increased (Australia and New Zealand Dialysis 
and Transplant Registry (AZDATA Registry), 2017a). At the end of 2015 there were 
approximately 23,000 dialysis and renal transplant patients, with roughly 2,500 undergoing 
PD (ANZDATA Registry, 2017b). Patients who are recommended PD are first required to 
undergo surgery to place a catheter into the peritoneal membrane in the lower abdomen. 
During dialysis exchanges, dialysate is infused into the peritoneum, which acts as a filter to 
absorb toxins, waste products, and water from the patient’s blood (Ellam & Wilkie, 2015). 
These are then drained into an external bag attached to the catheter that the patient discards at 
the end of therapy. Two forms of PD exist. Both are self-administered therapies that occur in 
the patient’s home. In the pre-dialysis phase, patients receive education about PD and training 
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in how to perform dialysis exchanges. Patients receiving continuous ambulatory peritoneal 
dialysis (CAPD) perform four to six manual dialysis exchanges throughout the day, a process 
that takes approximately thirty minutes. Automated peritoneal dialysis (APD) requires the 
patient to connect to a machine for approximately ten hours during the night, which performs 
dialysis exchanges automatically whilst the person sleeps (Ellam & Wilkie, 2015). APD is 
the more common form of PD in Australia (approximately 67% of PD patients) (ANZDATA, 
2017b) and whilst there is no clear evidence indicating it’s clinical superiority over CAPD 
(Rabindranath et al., 2007), it likely offers patients greater psychosocial benefits including 
independence from therapy during the day and thus decreased interference on occupational 
and social functioning (Tong et al., 2013). 
Quality of Life and Psychological Wellbeing 
Quality of life is a subjective and multifaceted construct, which poses challenges to its 
definition and assessment. However, agreement exists that it encompasses a number of 
intersecting domains including physical, material, social and emotional wellbeing, and 
development and activity (Felce & Perry, 1995). Quality of life has been defined as an 
individual’s perception of their position in life in relation to their cultural context, values, 
goals, expectations, standards, and concerns (Finkelstein, Wuerth, & Finkelstein, 2009). 
Psychological wellbeing may be considered both an independent concept and a key 
component of quality of life. Ryff (1989) argued that psychological wellbeing encompasses 
the six domains of self-acceptance, positive relations with others, autonomy, environmental 
safety, purpose in life, and personal growth. Health-related quality of life has been defined as 
the extent to which an individual perceives a medical condition and its treatment affects the 
physical, social, emotional, and therapeutic dimensions of their usual or expected functioning 
and wellbeing (Finkelstein et al., 2009; Guney et al., 2010). Although different in nature, 
many chronic diseases are common in their long-term trajectory and deleterious physical, 
GASTROINTESTINAL HEALTH IN END-STAGE RENAL DIESEASE 6 
economic, and psychosocial consequences for individuals and their families. Quality of life is 
therefore considered a critical issue in the assessment and management of patients with such 
conditions and has been extensively investigated in research, including among patients with 
varying stages of CKD (Edgell et al., 1996). 
The physical, psychological, and quality of life effects of end-stage renal disease 
and peritoneal dialysis. Whilst dialysis therapy offers patients the prolonging of life, it does 
not restore kidney function to normal. This has significant emotional and psychosocial 
consequences for patients, many of whom have to cope with the disease and its daily 
treatment for a number of years. It is therefore unsurprising that they experience poorer 
psychological wellbeing and quality of life compared to transplant recipients and healthy 
individuals (Maglakelidze, Pantsulaia, Tchnokhonelidze, Managadze, & Chkotua, 2011). For 
patients receiving PD, quality of life generally declines with time on dialysis in both physical 
and psychological arenas (Bakewell, Higgins, & Edmunds 2002; Lim, Yu, Kang, Foo, & 
Griva, 2016). The compromised psychological wellbeing of patients receiving PD may be the 
result of limited physical and functional capacity, symptom burden, medication side-effects, 
and treatment complications (peritonitis or catheter exit site infections) and subsequent 
surgeries. Patients also face a number of direct psychosocial difficulties as a consequence of 
the daily PD therapy regime, including lifestyle restrictions, sleep disturbance, changes in 
relationships, and social isolation (Guney et al., 2010; Tong et al., 2013). Thus, patients’ poor 
quality of life is likely explained by reciprocal interactions between a number of physiologic 
and psychosocial influences. The relationships between these factors are worthy of further 
research effort and clinical consideration in nephrology, as poor psychological status and 
quality of life are strongly associated with clinical outcomes in ESRD, including treatment 
nonadherence, morbidity, and mortality (Farrokhi, Abedi, Beyene, Kurdyak, & Jassal, 2014; 
Lew & Pirano, 2005). 
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Symptom burden has been established as a strong predictor of poor psychological 
status and lower health-related quality of life in patients with CKD (Almutary, Bonner, & 
Douglas, 2013; Almutary et al., 2016; Davis, Phillips, Naish, & Russell, 2002; Davison & 
Jhangri, 2010). In those receiving dialysis, multiple physical symptoms are suspected to 
result from uremia itself, as well as the secondary impacts of dialysis on physiology 
(Skroeder, Jacobson, Lins, & Kjellstrand, 1994). Research has shown that symptom burden is 
high among patients receiving PD, who consistently report fatigue, itching, muscle cramps, 
pain (Almutary et al., 2016; Figueiredo et al., 2012; Murtagh, Addington-Hall, & Higginson, 
2007) and a variety of GI symptoms (Cano et al., 2007) (to be discussed further later in this 
review). A literature review by Almutary et al. (2013) investigated total symptom burden of 
patients at CKD Stage 4 (pre-dialysis), Stage 5 (patients receiving hemodialysis (HD) or PD) 
and Stage 5 (conservative management). Findings revealed that compared to other CKD 
groups, the physical and psychological symptom burden of PD patients is understudied and 
not well understood, representing a significant gap in the literature. The same investigators 
(Almutary et al., 2016) therefore conducted a cross-sectional study comparing the 
multidimensional symptom experience (prevalence, severity, distress, and frequency) of 
patients either receiving HD or PD and those at Stage 4 not undergoing dialysis, using the 
CKD Symptom Burden Index. They found that symptom distress was significantly higher 
among the dialysis group than the non-dialysis group and that patients receiving PD reported 
an average of ten CKD-related symptoms. Furthermore, in all groups, fatigue was one of the 
most burdensome symptoms, but mostly so for those receiving PD. Whilst the prevalence of 
many symptoms is well-established in the CKD literature, less is known about their role in 
impairments to patients’ psychosocial wellbeing. As suggested by Almutary et al. (2016), 
level of symptom severity and associated distress contribute greatly to total symptom burden. 
Arguably, it may be these factors that have the greatest implications for patients’ mental 
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health and quality of life, highlighting that investigation of the patient’s symptom experience, 
particularly from their perspective, warrants further investigation. 
Patients undergoing PD experience psychological disorders more commonly than 
healthy individuals. It is estimated that the prevalence of depression is three to four times 
higher in CKD and ESRD groups compared to the general population (Lew & Piraino, 2005; 
Shirazian et al., 2017), with one systematic review and meta-analysis yielding estimates 
between 22.8% and 39.3% (Palmer et al., 2013). In patients receiving PD, depression is 
associated with inadequate nutrition, increased hospitalisations, lower quality of life, and 
possibly premature death (Lew & Piraino, 2005). The mechanisms underlying depression in 
ESRD are complex. High rates may be explained by similarities in somatic symptoms of 
depression and uremia, such as lack of energy, decreased appetite, and sleep disturbance 
(Christensen & Ehlers, 2002), in addition to the many psychosocial changes that accompany 
the progression to the final stage of renal failure and dialysis therapy. Delayed sleep onset, 
nighttime awakenings, and restless leg syndrome are also frequently reported by patients 
undergoing PD (Murtagh et al., 2007; Santos & Almondes, 2015) and are in turn, associated 
with depression and poorer quality of life (Guney et al., 2010). 
Although not as widely studied as depression, research has demonstrated that other 
psychological problems are commonly experienced by patients receiving PD. Prevalence 
estimates for symptoms of anxiety in dialysis patients range between 12% and 52% (Murtagh 
et al., 2007). For PD patients, worries about restrictions in daily life, changes in physical 
appearance, and fear of decline in physical function are common (Ye et al., 2008), as is body 
image disturbance (Partridge & Robertson, 2011). Physical appearance concerns are likely 
related to the visible bodily changes that result from dialysis including weight gain, 
abdominal stretching and bloating, and the permanent catheter, which may further exacerbate 
the sexual dysfunction many patients experience (Vecchio, Palmer, Tonelli, Johnson, & 
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Strippoli, 2012). Common sexual problems reported by both male and female patients 
include decreased interest in sex, low levels of sexual satisfaction, and difficulties with 
arousal and in achieving orgasm (Finkelstein, Shirani, Wuerth, & Finkelstein, 2007; Steele et 
al., 1996). Qualitative evidence has also revealed negative changes in patients’ attitudes 
towards sex in the presence of their disease and treatment (Vecchio et al., 2012; see also 
Yilmaz & Özaltm, 2011). Both married and single patients on PD express concerns regarding 
the impacts of the therapy on body image and sexual functioning, and perceive these as 
obstacles to current or potential future relationships (Yilmaz, 2010; Yilmaz & Özaltm, 2011). 
Sexual dysfunction in CKD is likely the consequence of biological and psychological 
aetiology, including hormonal abnormalities associated with renal failure, medications, and 
depression. For patients undergoing PD, changes in partner roles and relationships as a result 
of living with ESRD and undergoing therapy in the home may also contribute to these 
problems. In particular, for those who undergo APD whilst in bed, the machine, connecting 
cord, and catheter may pose particular intrusion on sexual relationships and physical 
intimacy. 
A number of qualitative studies have explored patients’ experiences and perceptions 
of living with ESRD and PD, revealing their varied psychosocial impacts. Tong et al. (2013) 
carried out a comprehensive thematic synthesis of 39 qualitative studies exploring patients’ 
experiences, beliefs, and attitudes about PD therapy. Studies included in the review 
predominantly explored topics including decision-making in dialysis treatment, advanced 
care planning, and treatment in the home environment. The authors identified seven major 
themes: resilience and confidence, support structures, overwhelming responsibility, control, 
freedom, sick identity, and disablement. For some patients, the control and independence 
offered by home PD was greatly valued and related to a sense of resilience and self-efficacy, 
particularly for those who perceived strong family, peer, and medical support. However, for 
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others, PD was seen as an overwhelming responsibility, intrusive, burdensome for families, 
and led to a sense of worthlessness. Patients also described impaired physical functioning, 
general fatigue, and damages to self-esteem and body image. Using the consolidated criteria 
for reporting qualitative research (COREQ) guidelines (Tong, Sainsbury, & Craig, 2007), the 
authors concluded that the comprehensiveness of reporting and quality of the studies included 
varied greatly. They also highlighted that 23 of the 39 studies reviewed omitted details of the 
PD modality of the study sample. This detail is important and should be considered in future 
study samples, as patients’ psychosocial concerns may vary depending on PD modality, 
particularly as CAPD and APD involve different routines at different times in the patient’s 
day-to-day life. 
The review discussed above highlights that the majority of qualitative studies 
conducted with patients receiving PD have assessed their broader opinions of the therapy. 
Only a small number have explored the interaction between physical processes or symptoms 
and patients’ psychosocial wellbeing. The findings of these studies support that of the 
quantitative literature, suggesting that sleep disturbance is a significant concern for PD 
patients. In a phenomenological study by Yngman-Uhlin, Friedrichsen, Gustavsson, 
Fernström, and Edéll-Gusafsson (2010) involving 14 patients on PD (nine CAPD and five 
APD), poor sleep not only resulted in daytime physical tiredness but patients also related this 
to mental drowsiness, irritability, stress, decreased mood, worry, and existential thinking. 
These factors interacted in a bi-directional manner with tiredness, which was described as a 
prolonged and ever-present feeling. Another study found that pre-dialysis, HD, and PD 
patients experienced fatigue in both mental and physical domains as central to their limited 
functional capacity, and described persistent lack of energy and strength (Heiwe, Clyne, 
Dahlgren, 2003).  
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The Gastrointestinal Health of Patients Receiving Peritoneal Dialysis 
Common gastrointestinal problems. As previously mentioned, GI problems are 
common in ESRD. In particular, between 32% and 85% of patients on dialysis report 
experiencing GI symptoms (Ariffin et al., 2016; Dong & Guo, 2010; Salamon, Woods, Paul, 
& Huggins, 2013; Shirazian & Radhakrishnan, 2010; Strid et al., 2002). Despite this variation 
in prevalence estimates, likely due to inconsistencies in symptom definitions and assessment 
tools used in the literature, GI symptoms are a well recognised feature of the symptomatic 
profile of patients undergoing PD. Constipation, diarrhoea, nausea, and abdominal pain are 
particularly common (Cano et al., 2007; Dong et al., 2014; Figueiredo et al., 2012), with 
some evidence suggesting these patients may be more susceptible to malnutrition and more 
severe gastroesophageal reflux and eating dysfunction than those undergoing HD (Affrin et 
al., 2016; Dong et al., 2014; Strid et al., 2002). Irritable bowel syndrome is also common, 
affecting up to one third of PD patients (Shirazian & Radhakrishnan, 2010). Such GI 
complications among patients on dialysis are multifactorial problems, resulting from uremia, 
diet, medication side-effects, and the impact of dialysis itself on GI function (Dong & Guo, 
2010; Yasuda et al., 2002). 
The relationship between gastrointestinal symptoms and psychosocial wellbeing. 
Although GI problems are a well-recognised feature of the ESRD patient’s experience, their 
relation to quality of life has been the subject of only few studies. A clear inverse association 
between gastrointestinal symptoms and psychological wellbeing and quality of life exists in 
the general population and patients with ESRD (Strid et al., 2002; Tougas, Chen, Hwang, 
Liu, & Eggleston, 1999). In dialysis groups, the connection between GI symptoms and 
quality of life has predominately been examined in observational research. For example, Strid 
et al. (2002) assessed the GI symptoms and general psychological wellbeing of 233 HD, PD, 
and pre-dialytic patients (Chronic Renal Failure (CRF) group) compared to healthy controls, 
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via the Gastrointestinal Symptom Rating Scale (GSRS) and the Psychological General Well-
Being index (PGWB index). Results showed that total GSRS scores were significantly higher 
among individuals with CRF than those without and that PD patients suffered from more 
severe reflux and eating dysfunction than other groups. Pre-dialysis and PD patients had 
similar PGWB index scores to healthy controls, however, a negative correlation between 
GSRS scores and the PGWB index was found. The authors concluded that in addition to the 
psychosocial consequences of dialysis, patients with high GI symptom profiles may be at 
increased risk of poor psychological outcomes. Another study, by Zhang et al. (2013), 
measured the incidence of constipation and its effects on the health-related quality of life of 
78 HD and 127 PD patients. Compared to those without constipation, patients who reported 
this symptom had significantly lower health-related quality of life scores, as measured by the 
12-item short form (SF-12) General Health Survey, and higher scores on the Beck 
Depression Inventory. Furthermore, although constipation was experienced by a greater 
number of HD patients, those undergoing PD with constipation had significantly worse 
health-related quality of life in both physical and mental domains. In contrast, Almutary et 
al.’s (2016) recent study found that PD patients had the highest incidence of constipation 
when compared to HD and pre-dialysis patients, and experienced the greatest distress with 
this symptom and decreased appetite. 
Research has further demonstrated that dialysis patients employ various strategies in 
an attempt to alleviate troublesome GI symptoms, which may have both physical and 
psychosocial consequences. Salamon et al.’s (2013) cross-sectional study assessed the 
prevalence of GI symptoms and their impact on food intake in 122 PD and 172 HD patients 
via a structured 10-minute interview conducted by a dietician. Patients responded “yes” or 
“no” to the question “do you suffer from any of the following symptoms?”, with reference to 
a range of GI symptoms including nausea, vomiting, early satiety, constipation, and diarrhea. 
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Results showed that not only were symptoms more prevalent in PD patients than HD patients 
(85% and 51% respectively), a significantly greater number receiving PD attributed the 
commencement of dialysis to the onset or worsening of GI symptoms (54.9%) and reported a 
decrease in food intake and dietary changes to improve them (33.6%). Participants reported 
strategies including substantially reducing fluid intake with meals, missing meals 
(particularly breakfast) or consuming plainer or softer foods, however, it is not clear how 
these data were assessed or analysed. Anorexia, classified by the authors as a GI symptom, 
was also reported in more than twice the number of PD than HD patients (48% and 22% 
respectively).  
Dietary management. To maintain health and manage comorbidities, patients 
receiving dialysis are often required to adhere to a prescribed renal diet and significantly 
restrict fluid intake. In conjunction with this, many experience decreased appetite and 
distorted taste (dysgeusia) (Affrin et al., 2016). Diet and fluid instructions can be met with 
difficulty and frustration by patients on dialysis, resulting in reduced adherence to the 
recommended diet (Palmer et al., 2015). Morris, Love, van Aar, Liles, and Roskell (2015) 
conducted semi-structured in-depth interviews with 10 PD patients to understand their 
experiences of following dietary advice provided by renal dieticians. A major theme, 
difficulty outside the home, originated from the data, revealing that patients’ described 
following dietary advice as particularly challenging when in public or social settings. Patients 
described eating foods reluctantly rather than disclosing their dietary needs to other people, a 
sense of frustration and restriction in dietary choice, and difficulties in dealing with social 
judgments about their dietary requirements. In extreme cases, some described declining 
invitations to social events at which they knew food would be present to avoid attention and 
judgment from others. These findings are consistent with that of Hollingdale, Sutton, and 
Hart’s (2008) study, which involved focus groups with ten pre-dialysis and ten dialysis 
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patients. Themes of self-discipline, low motivation, and confusion regarding dietary advice 
were also found, and patients reported their partners had also adopted the diet out of ease of 
preparing meals. In line with Salamon et al.’s (2013) quantitative study, patients reported 
self-imposed dietary changes in response to symptoms, such as refraining from eating foods 
that did not ‘agree’ with them. Given the evidence discussed, and that the preparation and 
consumption of food is at the center of many social interactions, dietary changes and co-
occurring GI problems could pose particular threat to the psychosocial wellbeing of patients 
on PD. In conjunction with other consequences of PD including changes in weight, physical 
appearance, and body image disturbance, these issues represent a complex group of factors 
that may lead to psychological outcomes for patients including depression and possibly, 
disordered eating. 
The mind-gut axis and chronic kidney disease. Growing evidence suggests a bi-
directional relationship between the gastrointestinal system, or the gut, and the brain, 
commonly referred to as the mind-gut axis. This axis involves communication between the 
central and the enteric nervous system by means of neural and hormonal links, influenced by 
the trillions of microbial cells harbored in the gut, or the gut microbiome (Carabotti, 
Scirocco, Maselli, & Severi, 2015). Not only are mind-gut interactions vital in the 
maintenance of gastrointestinal homeostasis, emerging research suggests they may also 
contribute to the coordination of one’s physical and emotional state, thus influencing the risk 
of various disorders (Foster & Neufeld, 2013; Mayer, Padua, & Tillisch, 2014). Experimental 
research in animal models supports the modulating effect of gut microbiota on the mind-gut 
axis, as reflected in an increase in stress reactivity and anxiety-like behaviour (Bravo et al., 
2011; Lou et al., 2014). In humans, associations have been established between microbial 
imbalance, or dysbiosis, and autism (Mayer et al., 2014; Song, Liu, & Finegold, 2004) and 
stress, anxiety, and depressive symptoms (Foster & Neufeld, 2013). 
GASTROINTESTINAL HEALTH IN END-STAGE RENAL DIESEASE 15 
Gut microbiome are modified by a number of physical, psychological, and 
environmental factors, including diet, antibiotic medication, and stress (Foster & Neufeld, 
2013; Wing, Patel, Ramezani, & Raj, 2016). Disruptions to mind-gut communications have 
been found in patients with gastrointestinal disorders. In particular, extensive research has 
shown the occurrence of dysbiosis in patients with irritable bowel syndrome, up to 94% of 
whom experience a comorbid psychiatric disorder, namely major depression and generalised 
anxiety disorder (DuPont, 2014; Whitehead, Palsson, & Jones, 2002). Similarly, emerging 
evidence also indicates modifications to the structure, diversity, and abundance of the gut 
microbiome of patients with CKD (Vaziri et al., 2012; Wing et al., 2016). This is attributable 
to the impacts of kidney failure itself and dialysis therapy, including lesions to intestinal 
barriers, secretion of ammonia and urea into the gastrointestinal tract, and decreased digestive 
capacity (Ramezani & Raj, 2014). In turn, unbalanced gut microbiota are said to contribute to 
the progression of CKD and associated comorbidities (Felizardo, Castoldi, Andrade-Oliveira, 
& Câmara, 2016). 
As seen in other populations, associations between irritable bowel syndrome, GI 
symptoms, and psychiatric disorders have been established in ESRD patients. Kahvecioglu et 
al. (2005) assessed this among 93 HD and 35 PD patients and 51 healthy controls who 
completed a series of questionnaires evaluating upper GI symptoms, irritable bowel 
syndrome, and psychological status. The prevalence of irritable bowel syndrome and 
psychiatric disorders was significantly higher among dialysis patients than controls, and 
among dialysis patients, significantly increased in the presence of anxiety and depression. In 
Cano et al.’s (2007) study, 100 HD and 48 PD patients completed the standardized Rome II 
questionnaire (Thompson, Irvine, Pare, Ferrazzi, & Rance, 2002), the results of which were 
compared with that of 148 medical outpatients and 148 healthy controls without renal failure. 
The prevalence of GI symptoms and irritable bowel syndrome was higher among dialysis 
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patients than other groups. The association between GI symptoms and anxiety and depression 
in PD patients was not examined, likely to due to small numbers, however, irritable bowel 
syndrome rates were significantly higher among PD patients than medical outpatients. This 
stands as an important finding given the established association between irritable bowel 
syndrome and anxiety and mood disorders (Whitehead et al., 2002), as previously discussed. 
Discussion 
It is well documented that ESRD and renal replacement therapies have significant 
deleterious consequences for patients’ psychological wellbeing and quality of life. As 
demonstrated in the aforementioned literature, in patients receiving PD, these issues have 
largely been examined in quantitative research employing various self-report measures. The 
fixed nature of such tools represent limitations to their assessment of wellbeing and quality of 
life, which are, inherently, subjective constructs. Data obtained by these generic instruments 
may therefore not reflect the patient’s priorities and experiences of dysfunction (Pugh-Clarke, 
Koufaki, Rowely, Mercer, & Naish, 2002). Furthermore, discrepancies between objective 
clinical variables and patient reported symptoms have been found in PD cohorts, for example, 
GI symptoms and levels of serum haemoglobin, albumin, urea and creatinine, fatigue and 
haemoglobin, and itchy skin and phosphorous (Affrin et al., 2016; Figueiredo et al., 2012; 
Thong et al., 2009). This may suggest that clinical interventions aimed at improving quality 
of life may not relate meaningfully to the patient’s experience (Murtagh et al., 2007) and that 
health professionals may be unaware of or underestimate the role of particular 
pathophysiology on patient wellbeing. Furthermore, whilst quantitative evidence has 
consistently shown that particular symptoms are highly prevalent among patients on PD, it 
may not be these that cause the greatest impairments to psychosocial wellbeing and 
functioning. 
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The literature reviewed also emphasises GI problems as a potential mechanism by 
which the psychological wellbeing and quality of life of PD patients are negatively impacted. 
Much remains to be learned about the consequences of altered gut microbiome in CKD, 
however, the emerging evidence of mind-gut axis communications suggests that this may be 
yet another mechanism placing patients with this condition at risk of poor psychological 
outcomes. In addition, the review highlights that dialysis patients report difficulties following 
dietary advice and attempt to control symptoms through changes in diet and eating behaviour. 
It is plausible to suggest that these behaviours may have additional negative consequences for 
patients’ lifestyle, relationships, nutritional status, and mental health. Given investigation in 
the theme of the mind-gut axis is in its infancy, more research is needed to further 
understandings of the role of GI and bowel health in CKD and accompanying psychological 
comorbidities (Ramezani & Raj, 2014). 
Despite the findings of the literature reviewed and the well-recognised prevalence of 
GI symptoms and psychological problems among patients receiving dialysis, the relationship 
between GI health, mental health, and quality of life remains unclear. Little is known about if 
and how GI complications play a role in impairments to dialysis patients’ mental and 
emotional wellbeing and impact their day-to-day lives. The paucity of qualitative studies on 
these topics may be one explanation for this gap in knowledge. At present, research 
employing quantitative methods dominates the literature in these areas, which can reveal 
associations but not an in-depth understanding of the patient’s experience. Most qualitative 
studies conducted with PD patients have investigated topics such as treatment decision-
making and advanced care planning, with few exploring patients’ multidimensional symptom 
experience and psychosocial wellbeing. Moreover, few of these qualitative studies have been 
conducted with patients on HD and PD separately, which may limit the transferability of 
findings to particular groups. Although evidence suggests there are no significant differences 
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in the health-related quality of life of patients receiving HD or PD (Ho & Li, 2016), 
qualitative exploration may reveal unique differences in the psychosocial concerns and needs 
of these individuals, which may not be detectable via quantitative methods. 
To address the discussed gaps and limitations of the current literature, it is suggested 
that qualitative methods be employed in future research with patients undergoing PD and 
other ESRD groups. This research would provide an in-depth understanding of what patients 
consider to be the most important issues in relation to their psychological wellbeing and 
quality of life. Given growing support for patient-centered care in nephrology (Tong & Craig, 
2016), the findings of qualitative research could provide great insight into patients’ 
experiences, values, and priorities to better inform shared-decision making and reveal 
potential areas of unmet need. 
Conclusion 
The present review demonstrates that although patients’ lives are maintained by 
dialysis, this often comes at significant psychosocial costs. However, further research is 
needed to explore how PD results in impairments to patients’ psychological wellbeing and 
quality of life. To the author’s knowledge, no qualitative study has explored the experiences, 
perceptions, and attitudes of PD patients regarding the impact of PD therapy on 
psychological wellbeing and quality of life, particularly focusing on the links between mental 
health, GI health, diet, and quality of life. Future qualitative research should attempt to 
contribute to the current CKD literature and the emerging field of mind-gut axis research by 
asking questions such as ‘what are the psychological consequences and quality of life impacts 
of PD?’ and ‘what are the psychosocial consequences of dietary changes and GI symptoms in 
patients receiving PD?’ This information would be useful for both health care professionals 
and patients, to integrate patient preferences with best available clinical evidence in the 
management of this life-limiting illness, particularly in its advanced stages. Given the 
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prolonged course of CKD and the profound psychosocial consequences of renal replacement 
therapies for patients and their families (Tong, Winkelmayer, & Craig, 2014), such research 
is crucial to promote patient wellbeing and quality of life.  
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Abstract 
Background: Patients receiving peritoneal dialysis (PD) for end-stage renal disease (ESRD) 
experience markedly poorer quality of life than healthy individuals. Gastrointestinal (GI) 
symptoms, including nausea, constipation, and diarrhoea, are prevalent and associated with 
poor psychosocial wellbeing among this patient group. Despite this, patients’ experiences of 
GI symptoms and their psychosocial consequences are yet to be explored.  
Study Design: Qualitative study. Setting & Participants: Participants were recruited through a 
Renal Unit at a public hospital in South Australia. Ten patients receiving automated PD (5 
females, 5 males) aged 31 to 77 years (M = 59.3) participated in a single one-on-one 
qualitative interview. Methodology: Qualitative interviews were audio recorded and 
transcribed verbatim. Analytical Approach: Interview transcripts were analysed using 
thematic analysis. Results: A central theme of Autonomy emerged from the data representing 
participants’ experiences of the psychosocial consequences of dialysis, GI symptoms, and 
dietary changes. This overarched two main themes of Loss of Autonomy (Sub-themes: 
Interference to Daily Life (Dialysis Process and Sleep, Impacts on Relationships), 
Powerlessness, Frustration, Food Aversion, and Restriction (Friendships and Social Life, 
Impacts on Partner)) and Attempts to Gain Autonomy (Sub-themes: Coping Well, 
Pragmatism, and Maintaining Normality). A related sub-theme of Partner as a Carer emerged 
as part of Loss of Autonomy. Limitations: Recruitment of patients of particularly poor health 
status was difficult and may therefore limit the transferability of findings. Conclusions: GI 
symptoms have psychosocial consequences resulting in various losses of autonomy for 
patients, which are linked to that of diet and fluid restrictions. Patients employ various 
strategies to attempt to regain autonomy in the face of these issues. Dietary education and 
symptom management advice should aim to enhance patient autonomy within the confines of 
PD therapy and thus aim to reduce its impact on psychosocial wellbeing. 
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Introduction 
Chronic kidney disease is a life-limiting illness characterised by the progressive and 
irreversible decline of kidney function.1 In its advanced stages, termed end-stage renal 
disease (ESRD), patients may choose a palliative care pathway or require kidney 
transplantation or dialysis therapy to survive. At the end of 2015, approximately 12,400 
adults were receiving dialysis for ESRD in Australia, a figure that has steadily increased in 
the last two decades.2 Whilst dialysis offers patients an increase in life length, it does not 
restore kidney function to normal and thus, may not completely revoke symptoms of the 
disease. In addition, dialysis itself can have profound physical and psychosocial 
consequences for patients, many of whom will have to maintain therapy for a number of 
years in the absence of accessible kidney transplantation. Problems resulting from ESRD and 
dialysis can include pain, poor gastrointestinal (GI) health, sleep disturbance, sexual 
dysfunction, psychological depression, and changes in lifestyle and relationships.3, 4, 5, 6, 7 
In ESRD, quality of life can be defined as the patient’s perception of the impacts of 
the disease and dialysis therapy on their physical, social, and emotional functioning and 
wellbeing.8,9 Psychosocial wellbeing may be viewed as an independent construct and as 
having significant influence on an individual’s quality of life. For patients receiving dialysis, 
factors relevant to psychosocial wellbeing include psychological status and relationships with 
individuals, family, and community.10 Whilst it is well recognised that patients receiving 
dialysis experience markedly poorer quality of life compared to renal transplant recipients 
and healthy individuals,5,11 greater exploration of the relationships between physical 
symptoms and psychosocial factors that contribute to quality of life decrements is required.  
Peritoneal dialysis (PD) is a home-based therapy for ESRD currently received by 
approximately 2,500 individuals in Australia.12 PD involves the infusion of dialysate fluid 
into the peritoneal membrane, or lining of the abdominal cavity, via a catheter in the patient’s 
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lower abdomen. The peritoneum acts as a filter during dialysis exchanges, performing the 
kidneys’ typical function of diffusing excess water and small solutes, such as urea and 
creatinine, from the patient’s blood.13 Two forms of PD exist. Patients receiving continuous 
ambulatory peritoneal dialysis (CAPD) manually perform four to six dialysis exchanges 
throughout the day, a process that takes approximately thirty minutes. Patients receiving 
automated peritoneal dialysis (APD) connect to a dialysis machine for approximately 10 
hours each night that automatically performs a series of cycling exchanges whilst the person 
sleeps.13 APD is the more common form of PD in Australia (67% of patients receiving PD for 
ESRD).12  
Previous qualitative research has explored patients’ experiences with and opinions of 
PD therapy, revealing its varied impacts on psychosocial wellbeing.7 For some patients, the 
home-based and self-administered nature of PD leads to a sense of control, self-efficacy, and 
freedom.7, 14 However, it can also disrupt their home environment, lifestyle, and partner 
relationships.7 In addition, the permanent abdominal catheter has negative impacts on 
patients’ body image, self-esteem, and sexual functioning.7, 15 It is plausible to suggest that 
these psychosocial difficulties may be particularly pronounced for patients undergoing APD, 
given that therapy occurs at night whilst the patient is in bed, which may be shared with an 
intimate partner. 
GI symptoms are common in ESRD. In particular, patients receiving PD frequently 
experience constipation, nausea, diarrhoea, vomiting, and abdominal pain,4, 16, 17 as well as 
decreased appetite and dysgeusia (distorted taste).18 One third are also estimated to be 
affected by irritable bowel syndrome.19 Such GI complications are multifactorial problems, 
resulting from medication side-effects, diet, and the impacts of dialysis itself on the 
gastrointestinal tract.20, 21 Quantitative research has demonstrated that GI symptoms are 
negatively associated with psychological wellbeing and quality of life among patients 
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receiving dialysis.3, 22, 23 A study by Zhang et al.23 assessed the incidence of constipation and 
health-related quality of life of 78 hemodialysis (HD) and 127 PD patients and found that 
those who reported experiencing this symptom had significantly poorer health-related quality 
of life and higher levels of depression than those who did not. Moreover, patients receiving 
PD with constipation had significantly worse quality of life in both physical and mental 
domains than those undergoing HD. Similarly, Strid et al.’s22 study found an inverse 
association between gastrointestinal symptoms and general psychological wellbeing among a 
sample of dialysis and pre-dialytic patients. Other research has shown that constipation and 
decreased appetite are associated with high levels of distress in patients receiving PD.3 Whilst 
GI problems are well recognised among this patient group, research suggests that their 
multidimensional symptom experience is understudied and less understood compared to that 
of other chronic kidney disease patients.3 As symptom burden has been identified as a 
predictor of poor psychological status and lower quality of life in chronic kidney disease, 24, 
25, 26, 27 the patient’s experience of symptoms is therefore worthy of further investigation. 
Dietary modification is an important aspect of the management of chronic kidney 
disease. Official guidelines recommend that patients receive expert dietary advice, with the 
aim of reducing protein, salt, phosphate, and potassium intake, appropriate to their level of 
renal function and associated comorbidities.28 Whilst diet and fluid restrictions are necessary 
for effective dialysis therapy, patients perceive them as burdensome and to have negative 
implications for their social life and relationships.29, 30, 31, 32 For example, in a recent study by 
Morris et al.30, patients on PD expressed frustration at their limited dietary choice and 
reported difficulties in dealing with judgments from others about their dietary needs. This led 
some patients to decline invitations to social events. Another study by Hollingdale et al.29, 
involving focus groups with patients in the pre-dialysis phase and patients receiving dialysis, 
yielded similar findings. Some participants in this study also described ceasing eating 
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particular foods in response to symptoms (i.e. those that did not ‘agree’ with them) and that 
their partners had adopted the same renal-specific diet out of ease of preparing meals. Other 
research has found that patients on PD employ self-imposed dietary and eating strategies in 
an attempt to avoid or improve GI symptoms.33 Given this research, it is plausible to suggest 
that diet and fluid restrictions, co-occuring GI symptoms, and subsequent changes in eating 
behaviour may be closely related and have deleterious consequences for patients’ physical 
health and psychosocial wellbeing. 
The mind-gut axis represents another potential mechanism by which GI symptoms 
may be linked to poor psychological status among patients with ESRD. The mind-gut axis 
consists of a bi-directional relationship between the central and enteric nervous system via 
various endocrine, immunologic, and hormonal networks.34 It has been proposed that the 
mind-gut axis influences not only hemostasis of the GI system, but also affect and stress-
related behaviours.34, 35, 36 Emerging evidence suggests that mind-gut axis interactions are 
predominantly influenced by the trillions of microbial cells, known as the gut microbiome, 
distributed in the human GI tract.34 These are susceptible to alteration from a number of 
factors including environmental stress, antibiotic medication, and diet.35, 37 Research has 
revealed microbial imbalance, or dysbiosis, in patients with irritable bowel syndrome, up to 
94% of whom experience comorbid psychological problems.38, 39 Whilst limited, more recent 
evidence has shown similar patterns in the microbial landscape of the intestines of individuals 
with chronic kidney disease.37, 40 In line with the mind-gut axis, research suggests that 
psychological distress, namely anxiety and depression can influence the onset and severity of 
GI symptoms.41, 42 In patients with irritable bowel syndrome, gastrointestinal-specific 
anxiety, which includes worry about and vigilance and sensitivity to GI sensations and 
symptoms, has been established as a predictor of symptom severity and overall quality of 
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life.43 These patients also describe constant anticipation of the next symptom episode and 
have identified stressful situations as a trigger for their occurrence.44 
Despite the existing evidence, a gap remains in the literature as to if and how GI 
symptoms contribute to impairments in the psychosocial wellbeing of patients receiving 
dialysis. The dearth of qualitative research into this topic may account for this gap in 
knowledge. Numerous qualitative studies have explored patients’ experiences and 
perceptions of PD therapy,7 however, to the author’s knowledge, none have explored their 
experience of GI symptoms and their potential psychosocial consequences. Qualitative 
exploration would elicit rich and detailed information of patients’ experiences, opinions, and 
perceptions, to reveal how dialysis contributes to decrements in quality of life. 
The aim of this study is to explore the perspectives, attitudes, and experiences of 
patients with ESRD undergoing PD, with a particular focus on the links between diet, 
gastrointestinal health, and psychosocial wellbeing. Through qualitative methods, this study 
asks the question: What are the psychosocial consequences of peritoneal dialysis, the renal 
diet, and gastrointestinal symptoms in patients with end-stage renal disease? Given patients’ 
desire for holistic care32 and the association between low quality of life and clinical 
outcomes,5, 45, 46 this area of investigation is of applied interest to patients as well as health 
professionals working in nephrology. 
Methods 
Study Setting and Participants 
This study was conducted through a Renal and Transplantation Service and 
Nephrology Unit at a tertiary public hospital in South Australia. The unit provides inpatient 
and outpatient treatment for individuals with chronic kidney disease, including kidney 
transplantation and dialysis therapy (HD and PD), across metropolitan and country areas of 
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South Australia. Participants were recruited from a Nephrology Unit and Dialysis Centre in 
South Australia through a purposive sampling strategy. Potential participants were those 
receiving PD (either CAPD or APD) for ESRD. Nephrologists initially nominated a list of 
suitable patients as potential participants. Nurses then approached potential participants at 
outpatient appointments or via telephone, to invite them to participate in the study and 
provided them with a participant information sheet and consent form. If interested, 
participants’ verbal consent was obtained for the author (primary researcher) to contact them 
to discuss the study in more detail and arrange an interview. If the patient was initially 
approached via telephone, the participant information sheet and consent form were posted to 
them by the author after telephone contact was made. During this phone call the author 
assured participants of confidentiality, emphasised that participation was voluntary and 
would in no way affect their current or future medical care, and of their right to withdraw 
from the study at any time. In total, 14 patients were invited to participate in the study. Four 
declined, with two indicating they were too time poor and burdened by health and treatment 
commitments and one provided no reason. One participant withdrew from the study after 
arranging an interview due to a decline in their health. 
Participants (N = 10) were five men and five women whose ages ranged between 31 
and 77 years (M = 59.3). All participants were undergoing APD. The length of time since 
commencing their current therapy ranged from one month to two years. Three participants 
had received previous renal replacement therapies, including HD, CAPD, and kidney 
transplant. Nine participants were married and one was single. Nine of the ten participants 
had children, ranging from preschool to older adult age. Two participants were working and 
eight were not in the paid workforce. Two participants had previously diagnosed 
psychological disorder, managed with psychotropic medications.  
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Data Collection 
A single one-on-one qualitative interview was conducted by the author with each 
participant between April and June 2017. The author was a female provisional psychologist 
receiving training in conducting qualitative research and had no prior relationship with the 
participants. Nine interviews were conducted face-to-face in a private consulting room at the 
Nephrology Unit or Dialysis Centre and one was conducted via telephone due to the 
participant living far away from these locations. Interviews only occurred once the 
participant’s written informed consent was obtained via the consent form. The interview 
guide was informed by previous research examining the gastrointestinal health, psychological 
wellbeing, and quality of life of patients receiving dialysis. A preliminary interview took 
place with a renal dietician acting as a patient, to assess the relevance of the interview 
questions in relation to the study aim. Participants were first asked basic questions about their 
demographic details and disease and treatment history. They were then asked “Can you tell 
me about how peritoneal dialysis has impacted your life?”. All participants were asked “Do 
you experience gastrointestinal, or gut, symptoms, such as nausea, diarrhoea, and 
constipation?”. The remaining questions and prompts were determined by the participant’s 
responses and included topics related to quality of life, relationships, diet, and mental and 
emotional wellbeing. Interviews lasted between 57 and 99 minutes (M = 72.3) and were 
audio recorded with the participant’s consent. All interviews were transcribed verbatim. To 
protect participant anonymity and confidentiality, all identifiable information was removed 
from the transcripts and they were each assigned a number. All participants were offered a 
copy of their interview transcript to make corrections or comment if they desired. Data were 
collected until theoretical saturation was reached; when no new emerging themes were 
attainted from the data.47 
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Data Analysis 
The data were analysed using the Framework approach, a variant of thematic 
analysis.48 Framework analysis allows the identification of themes in the data through 
inductive and deductive methods. The researcher engages in a fluid process of analysis across 
five stages, during which constant comparisons are made within and across the interview 
transcripts. As outlined by Pope et al.48 the first stage, familiarisation, begins at data 
collection as each interview is conducted, transcribed, and re-read, to allow the point of 
saturation to be identified. Second, the researcher begins identifying the thematic framework, 
applying emerging codes, themes, and concepts to the transcripts. Third, the researcher 
indexes all of the themes by systematically applying the thematic framework to the data. 
Fourth, the data are rearranged and synthesised into a chart by subject area and theme. 
Finally, the chart is used to develop a concept map, demonstrating associations between 
themes and to support their interpretation in relation to the research question. An audit trail 
was maintained throughout all stages of data collection and analysis to ensure rigor and 
trustworthiness. This detailed the author’s thoughts and reflections on each interview, 
emerging themes, any changes to the thematic framework, and explanations of decisions 
made throughout the data analysis process. For consistency, all interview transcripts and 
identified themes were reviewed by a supervising researcher who had experience in 
conducting qualitative research and using thematic analysis. The final findings and concept 
map were peer reviewed by the research group of the hospital’s Nephrology Unit, consisting 
of nephrologists, nurse practitioners, dieticians, and researchers (see Appendix B).  
Ethics approval to conduct this study at the relevant hospital and dialysis center was 
obtained from the hospital’s Research Ethics Committee (HREC Reference number: 
HREC/16/RAH/523) and the University of Adelaide Human Research Ethics Committee. 
Whilst staff of the hospital identified potential participants and two of the co-investigators of 
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the project were treating nephrologists, these people were not involved in the interviews nor 
had access to any form of the interview transcripts. 
Results 
A central theme of Autonomy emerged from the data representing participants’ experiences 
of the psychosocial consequences of dialysis, GI symptoms, and diet and fluid restrictions.  
This overarched two main themes of Loss of Autonomy and Attempts to Gain Autonomy. 
Loss of Autonomy encompassed sub-themes of Interference to Daily Life (Dialysis Process 
and Sleep, Impacts on Relationships), Powerlessness, Frustration, Food Aversion, and 
Restriction (Friendships and Social Life, Impacts on Partner). Restriction and Interference to 
Daily Life were related to another sub-theme; Partner as a Carer. Attempts to Gain Autonomy 
encompassed sub-themes of Coping Well, Pragmatism, and Maintaining Normality. The 
associations between sub-themes identified in the data are demonstrated in the concept map 
in Figure 1. 
Loss of Autonomy 
Interference to daily life. Participants reported experiencing GI symptoms of nausea, 
diarrhoea, vomiting, reflux, constipation, excessive flatulence, stomach cramps, and dry 
retching. Some expressed uncertainty about what preceded these symptoms, whilst others 
attributed them to the consumption of foods high in sugar, fiber, or fat. Participants described 
GI symptoms as an additional dialysis-related burden and disruptive to their day-to-day 
activities. Some described planning their day in anticipation of potential diahorrea, or taking 
longer to get ready in the morning due to nausea and vomiting. Another participant described 
frequent bowel movements as limiting to their ability to participate in and gain pleasure from 
particular activities, due to the recurrent need to go to the toilet and fear of not finding one 
when in public. 
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“I really-, like I can’t go shopping really. I can’t wander around the shops. I have 
to, I have to know where every public toilet is wherever I go because I know I’ll be 
visiting it. And you know, like, where were we somewhere the other day, and I said 
‘Oh I’ve got to go’ and [partner] goes ‘Not again!’ and I’m going ‘Yeah, 
again!’”(P3, Line 154) 
 
Dialysis process and sleep. Participants described recurrent bowel openings, reflux, 
and constipation as disruptive to the dialysis therapy. One participant reported abdominal 
pain had at times been severe enough to preclude them from sleeping and others described 
their bowel functions as inhibiting to the dialysis exchanges. Patients reported that when their 
bowels were not sufficiently empty, this would cause the dialysis machine to beep repeatedly 
and thus, disrupt their sleep. For one participant, their unpredictable bowel openings in the 
evenings meant that they often had to re-commence the time-consuming routine of preparing 
and connecting to the dialysis machine, including hand washing processes. 
 
“But there’s other issues too I think, I’m not quite sure, you know, you’ve got to 
make sure that your bowels are completely empty before you go on the [dialysis] 
machine otherwise it doesn’t work properly. So, you’ve got to think of these things 
so you make sure that everything is right-, the conditions are right for dialysis to 
work.” (P1, Line 150) 
 
Impacts on relationships. Participants also perceived negative impacts of GI 
symptoms on other people, including friends and partners. Some described feeling like an 
impost to other people due to their unpredictable GI symptoms and frequent need to use the 
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toilet during outings. Others were conscious of restraining symptoms, namely flatulence, out 
of fear of embarrassment or offending others. 
 
“You’ve got to be very careful. Restrain yourself in a lot of ways and be careful. 
[…]It gets very, very hard. […]Well, you can’t-, you’ve got to be a bit more 
respectful towards other people.” (P5, Lines 456, 458, & 460) 
 
One participant described the anticipation of GI symptoms, in addition to the 
abdominal catheter, as contributing to their decreased interest in sex since commencing APD. 
 
“I mean, my whole body image… it’s [catheter] this horrible thing in my stomach 
and um, you know, am I going to need to go the toilet in the middle of sex - oh that’s 
really nice isn’t it?! No. Not good.” (P3, Line 364) 
 
Powerlessness. Participants perceived a loss of autonomy and control within what 
was described as a confusing web of consequences resulting from ESRD and PD, including 
diet and fluid restrictions, GI symptoms, changes in body shape, weight gain, fluid retention 
from dialysis, and an inability to exercise. These problems were perceived to be interlinked 
and affected one another in a cumulative manner. Participants reported attempts to gain 
influence over one or more of these issues, however, frequently became frustrated and 
discouraged when their efforts resulted in further problems or they received subsequent blood 
test results that were unfavourable. Participants felt they were confined by the limits of their 
condition and powerless to effectively gain control over these issues, with some describing 
themselves as servants or bystanders to PD. Some participants described feeling 
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uncomfortable in their bodies and perceived themselves as physically unattractive as a result 
of these issues. 
 
“So, I’m probably more mindful of um, trying to have a reasonable diet to just 
manage the weight cos I feel like I’m not really in control of my weight anymore. 
[…] That’s probably the one thing that’s um, a frustration, more than anything else, 
cos I can’t really-, I don’t feel like I’ve got control over it. It’s like I’m a bystander 
to whatever happens with dialysis, just results in X, Y, Z.” (P4, Lines 120 & 122) 
 
Frustration. As a result of their various losses of autonomy, participants described a 
strong sense of frustration. Some experienced GI symptoms as particularly annoying. Many 
felt frustrated at their repeated efforts to monitor their bowel health and successfully manage 
GI symptoms, particularly given the strong emphasis placed on these issues by dialysis 
nurses. Despite experiencing frequent and distressing GI symptoms, one participant had not 
sought medical advice to improve these as they reported managing other symptoms and 
health issues was burdensome enough. 
 
“I don’t know what’s up with them, but it’s really annoying. But then the girls 
[nurses] will say ‘Don’t get constipated, don’t get constipated’, so I don’t get 
constipated. I eat lots of roughage. I mean, I’ve been to the toilet twice today 
already, I know I’ll go again this afternoon and again this evening. I just get sick of 
it. […] Yep. Sick, sick, sick of it.” (P3, Lines 124 & 126) 
 
Food aversion. Participants described a loss of autonomy over food preferences and 
choices. This was perceived to be a result of a complex interaction of factors including 
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changes in the taste, texture and smell of foods, loss of appetite, and GI symptoms, namely 
nausea, vomiting, and gagging. Participants described aversions to foods high in protein and 
fat, which were associated with a strong sense of disgust, feeling nauseous, and the urge to 
vomit. Participants’ appetite and interest in foods frequently changed. Some therefore 
described a discrepancy between their psychological desire for particular foods and their 
body’s ability to comfortably consume them. Changes in tastes for foods and food aversions 
were strong and inexplicable. For some participants, this lead to a loss of pleasure in eating 
experiences and a sense of disappointment. 
 
“So, I used to love nothing more than a really nice rump steak with a red wine-, 
um. […] Annoyed is not the word. Disappointed. Something I liked so much which I 
can’t even stand the- ((Leans away and grimaces)). But lots of foods are doing that 
to me at the moment. Um, I couldn’t hardly eat last night either, for feeling like that 
and it’s usually only in the mornings I feel like that but-, but last night I just noticed 
that I couldn’t-, I wasn’t coping with the meal that was in front of me and there was 
nothing wrong with it.”  (P8, Lines 359 & 363) 
 
Restriction. Participants described feeling restricted by the renal diet requirements. 
They perceived limited freedom to choose what they could eat and drink, which resulted in 
negative emotions including anger and frustration. 
 
“Um, it’s… it’s the worst thing ever. I really hate it [fluid restriction]. When I went 
on this [APD] they said ‘Oh you won’t be on a fluid restriction’, but within-, I 
wouldn’t be on a fluid restriction and that was fine. Cause I’m a big drinker. I like 
drinking. And, I just find it’s the worst thing, that’s what really, really pisses me off, 
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more than my guts, is that fact that I can’t have a nice, big, cold glass of cordial 
and just chug it down and think ‘Yeah that was nice’ and have another one if I 
wanted.” (P3, Line 186) 
 
Friendships and social life. Some participants described adhering to the renal diet as 
particularly challenging when eating in public with other people. This affected one 
participant greatly, who reported their dietary requirements had at times prohibited them from 
accepting invitations to eat out with friends. 
 
“Yeah, sometimes when my friends call me to go out I just don’t, I can’t be bothered 
sometimes. I feel that because they basically can have a drink of wine or stuff like 
that, and I basically can’t. Or they might go out certain places where they can eat 
certain foods and I can’t, it’s like-, well sometimes I think like, ‘Why am I 
bothering?’, like ‘Why should I go out for?’” (P6, Line 150) 
 
Impacts on partner. Participants in a relationship described the negative impacts their 
renal diet requirements had on their partners. Many reported that their partners had adopted 
the same diet out of ease of preparing and cooking meals. Participants perceived adhering to 
the renal diet as an unfair inconvenience and restricting for their partners as well as 
themselves. 
 
“So there’s a bit of fiddling around for her [partner]. And I don’t like greasy foods, 
uh, yeah. And she said I’m not a pleasure to cook for. […] Her diet is based around 
mine basically. […] Boring for her, yep. She’d like uh, yeah, she’d like [to], you 
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know, cook up a curry or stuff she likes but she’s restricted.” (P2, Lines 185, 247, & 
249) 
 
Partner as a carer. Participants described their Partner as a carer and assistant to the 
PD therapy. Some participants reported that their partners had adopted the responsibility of 
monitoring their food intake and preparing biochemically appropriate foods since 
commencing dialysis. Participants described their partners’ additional designated “jobs”, 
such as ordering treatment supplies and medications, lifting heavy fluid boxes, organising 
appointments, and cleaning and preparing the dialysis machine for use at night. Two 
participants described themselves as passive recipients to dialysis therapy that their partners 
‘did for’ them and being unaware of the specific equipment or fluids involved in their 
treatment.  
 
“You name it, you can’t eat it. You know, that’s-, it’s very much-, as I said, if it 
wasn’t for [partner] ((Chuckles)), for the food, I’d be as fat as a pig and probably 
dead by now. […] [She is] my nurse, my cook, my chauffer, what else… You name 
it-, my secretary. She’s the lot. Couldn’t ask for any better.” (P5, Lines 366 & 500) 
 
Attempts to Gain Autonomy 
Coping well. Overall, participants reported that they coped well with their GI 
symptoms. Participants mostly relied on medications to reduce the frequency of their 
occurrence, which they perceived to be effective. They described employing other simple 
strategies to gain relief when GI symptoms caused physical discomfort, including engaging in 
a relaxing activity or eating. One participant described using humour to diffuse the impact of 
GI symptoms when around others. Participants reported adjusting well to changes in their 
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bowel function and GI symptoms, with one describing their multiple bowel movements each 
day as the new “normal”. Participants sought advantages to GI symptoms, such as a decrease 
in appetite and not needing to use the toilet frequently. Some described feeling drained or 
lacking in energy after experiencing GI symptoms of nausea and diahorrea, however, GI 
problems were not perceived to have a significant impact on participants’ psychological or 
social wellbeing. 
 
“…that still happens to a certain extent now, that if I’m going to have a bowel 
motion and I get cleaned out I’ll go three times in about an hour. […] And so, that’s 
become me, that’s become normal, so…” (P9, Line 450 & 452) 
 
Pragmatism. Participants reported being accepting of their renal diet as part of the 
management of their condition and were pragmatic about making necessary changes. One 
participant described consuming food for nutritional benefit only rather than enjoyment. 
Some participants described compensatory strategies, such as replacing salt with large 
quantities of pepper or eating when thirsty. This pragmatic coping style was evident also in 
participants’ responses to GI problems. 
 
“It’s alright. I just wish I could eat a bigger range of goodies, um, but it’s no real 
problem. Because I just eat now because I’ve got to. I’ve got to get that goodness 
into me. So, it’s no big deal. I don’t get excited that it’s lunchtime.” (P2, Line 229) 
 
Maintaining normality. Some participants described ambiguity about dietary 
requirements and reported consuming foods they suspected to be prohibited in an attempt to 
maintain normality. Participants described eating desired foods to break the monotony of the 
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renal diet and not deprive themselves, adopting an ‘it’s all in moderation’ attitude. One 
participant reported frequently giving in to cravings and proceeding to eat foods they knew 
they should not. 
 
“No, because I still like cravings for cheese ((Chuckles)). […] And cheese is not a 
good thing either ((Chuckles)). […] But sometimes you know, I’ll go through a ‘yes 
cheese, cheese, cheese, cheese’ and then I thought ‘No I don’t want cheese’, so 
obviously I’m needing something-, to me, if I’m craving it I’m needing it…and so 
you know, it’s easier just to give it in.” (P9, Line 504, 506, 508 & 510) 
 
Discussion 
The purpose of the current study was to explore the psychosocial consequences of 
PD, the renal diet, and GI symptoms in patients with ESRD. This research identified that 
patients experience a Loss of Autonomy in the various psychosocial impacts of dietary 
changes and GI symptoms and respond to these with Attempts to Gain Autonomy. This 
central theme of Autonomy is consistent with previous qualitative research that has explored 
patients’ broader experiences and opinions of PD therapy. Such evidence has demonstrated 
the numerous psychosocial impacts of PD, yet that many patients perceive it to be a treatment 
that offers them opportunities to become self-determining, independent, and gain a level of 
control in the management of their condition.7 Prior to this study, research had established 
that GI symptoms were associated with poor psychological wellbeing and quality of life 
among dialysis patients, but how and why this was, had yet to be established. To the author’s 
knowledge, this study is the first to employ qualitative methods to explore the experiences 
and perceptions of patients receiving PD regarding GI symptoms and their psychosocial 
impacts. The overall findings extend the chronic kidney disease literature by demonstrating 
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that patients perceive various losses of autonomy in the psychosocial consequences of GI 
symptoms, which are perceived to be closely linked to that of the renal diet and the PD 
regimen. Patients meet many of these perceived losses of autonomy with pragmatic attempts 
to regain it, including self-directed or professionally recommended strategies, as well as 
changes in eating behaviours and attitudes that provide a sense of normality. When 
successful, these efforts and strategies increase autonomy, promote the patient’s psychosocial 
wellbeing and ultimately, help them cope well. However, patients feel frustrated and 
discouraged when attempts are inhibited by the confines of ESRD and PD therapy, or result 
in additional symptoms and difficulties. Patients’ grappling with losses of autonomy and 
attempts to regain it was found to be a dynamic and continual process.  
Consistent with previous research,4, 16, 17 participants in the present study reported 
experiencing a range of GI symptoms, which were identified as an Interference to Daily Life. 
Frequent and unexpected bowel movements impacted daily routines, the dialysis process, 
sleep, and the ability to enjoy particular leisure activities. Participants were wary of the 
perceptions of friends, family, and partners regarding their GI symptoms. It was noted that 
one participant described the anticipation of needing to unexpectedly defecate as contributing 
to their decreased interest in sex since commencing dialysis. The consequences of GI 
symptoms in patients’ day-to-day lives identified in this study are novel findings to add to the 
chronic kidney disease literature and provide new insight into the mechanisms by which GI 
symptoms contribute to quality of life impairments. Interestingly, similar psychosocial 
difficulties resulting from GI dysfunction have been described by patients with irritable 
bowel syndrome and irritable bowel disease, who commonly experience anxiety, social 
isolation, and exhibit avoidance behaviour due to fear of incontinence.39, 44, 49 In the present 
study, despite participants’ frustration due to the impacts of GI symptoms on their lives, they 
identified as Coping Well with them due to the use of adaptive and pragmatic strategies. 
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Furthermore, despite evidence of the mind-gut axis connection,34, 37, 40 participants in the 
current study did not describe experiences indicative of this. Given the emerging field of 
mind-gut axis research and the extensive literature on the relationship between psychological 
status and functional gastrointestinal disorder symptoms,41, 43, 44 it was anticipated that 
participants may describe incidences of stress, anxiety, low mood, or catastrophising as 
preceding or exacerbating GI symptoms. Although an explicit relationship between 
psychological status and GI symptoms was not described, the findings of this research 
demonstrate that patients perceive GI symptoms to play a role in the broader psychosocial 
impacts of PD. 
Participants described a sense of Restriction in dietary choice and loss of autonomy in 
freedom to consume foods and amounts of liquid they desired. Some described particular 
difficulty adhering to diet and fluid restrictions when outside the home, having implications 
for one participant’s social life. These challenges have been described by patients with 
varying stages of chronic kidney disease in previous research. The current findings therefore 
re-iterate that the renal diet can lead to interpersonal difficulties and negatively impact quality 
of life. 29, 30, 31 In alignment with Salamon et al.’s 33 study, some participants described self-
directed eating behaviours to alleviate GI symptoms. Participants also identified Pragmatism 
and Maintaining Normality in dietary management strategies and attitudes as central to 
regaining a level of autonomy in the face of diet and liquid restrictions. These efforts 
ultimately help patients to accept diet and liquid restrictions as part of their health 
management and comply with dietary instructions. This view is in alignment with the themes 
of accepting responsibility and valuing self-management identified in Palmer et al.’s31 review 
of qualitative studies about diet and fluid restrictions in chronic kidney disease.  
Participants described being dependent on their partner to monitor their nutritional 
intake and prepare appropriate food in accordance with the renal diet. Many participants 
GASTROINTESTINAL SYMPTOMS AND WELLBEING 53 
reported that their partners had adopted the same diet and had taken on other roles and 
responsibilities in their PD therapy. Participants described their Partner as a Carer and as 
actively involved in their health care, referring to them as their “nurse”, “carer”, and “cook”. 
Similar findings have been reported in other qualitative studies revealing the implications of 
dietary changes and PD therapy on partner roles and responsibilities within the relationship.31, 
50 Given patients commonly rely on their partners for various forms of support, further 
qualitative research is needed to explore the experiences, perceptions, and opinions of these 
individuals. Not only may this information lead to the enhancement of patient treatment 
adherence and thus outcomes, the findings of the present study suggest that partners may too 
experience losses of autonomy, having potential implications for their own psychosocial 
wellbeing. 
Participants also identified Food Aversion as a loss of autonomy over food 
preferences and eating experiences. Aversions to particular foods were experienced as 
powerful and bewildering, and for some participants, resulted in disappointment and a loss of 
pleasure. This change in the emotional and mental experience of eating has been identified in 
other studies with dialysis and non-dialysis patients, who report “feeling deprived” of 
pleasurable experiences due to dietary limitations and changes in taste.31 Food Aversion was 
described as a physical and psychological experience, whereby the participant’s body would 
reject food through nausea and gagging, as well as strong sense of disgust. To the author’s 
knowledge, this theme had yet to be identified in the qualitative literature. These findings 
complement the existing evidence regarding patients’ experiences of diet and liquid 
restrictions, by demonstrating that GI symptoms and changes in appetite and taste also 
contribute to its impacts on their lives. 
Participants described a loss of autonomy in navigating the competing demands and 
consequences of ESRD and PD, including dietary changes, GI symptoms, changes in body 
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shape, weight gain, fluid retention, identified as Powerlessness and Frustration. Participants 
attempted to master solutions to these problems, but became frustrated when they were 
inhibited by dietary and liquid restrictions, or an inability to exercise due to the time 
consuming PD regimen or treatment complications. This continual process was “physically 
and mentally draining” and often resulted in patients feeling powerless, subservient to the PD 
therapy, and for some, dissatisfied with their body image. These concerns and attempts to 
master PD and adjust to dietary changes have been reported consistently in the literature.7, 31 
The present study highlights that patients perceive GI symptoms to be closely related to these 
issues and feel responsible to manage them successfully due to the strong emphasis placed on 
bowel and gastrointestinal health by treating healthcare professionals. 
The central theme of Autonomy identified in the present study is consistent with 
previous research with patients with ESRD.7 Autonomy, control, and self-management have 
been established as important factors for successful psychological adjustment to the 
challenges posed by living with chronic disease.51 Opportunities to enhance patient autonomy 
in PD therapy may foster treatment compliance, a function that patients have described 
enables them to maintain a state of relatively normal health and being.52 ESRD and PD pose 
inevitable limitations on patients’ lives, which have far reaching psychosocial consequences. 
The current findings indicate that within these confines, patients attempt to reformulate their 
attitudes, behaviours, and environments to regain some level of autonomy and control that 
has been lost with varying degrees of success, a view that has also been reported elsewhere.53 
Regaining a level of autonomy helps the patient to feel self-efficacious and maintain a sense 
of normality whilst living with a life-limiting illness. The concept map identified in the 
present study, which highlights the dynamic processes between losses of autonomy and 
attempts to regain autonomy, may potentially be applied to understand the patient’s 
experiences of other problems resulting from ESRD and renal replacement therapies, for 
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example, pain, frailty, and identity changes. This conceptualisation may enable the 
identification of opportunities for strategies and interventions that promote patient autonomy 
and thus, improve patient psychological wellbeing and quality of life. 
The results of the present study are of applied interest to patients, nephrologists, renal 
nurses, and renal dieticians. The findings indicate that to promote patient psychosocial 
wellbeing and adaptive coping behaviours, opportunities that foster patient autonomy in 
dietary and GI symptom management should be considered. Furthermore, as has been 
suggested elsewhere,31, 54 patients’ partners may be included during the provision of dietary 
education and advice to improve recall of nutritional information and adherence to dietary 
instructions. However, the psychosocial difficulties faced by patients and their partners that 
were identified in the present study highlight that the burden of PD should not be 
underestimated. Despite the participants of the present study demonstrating positive 
psychological adjustment overall, for some patients and arguably their partners, 
psychological support may be beneficial. The psychosocial burden associated with PD, GI 
symptoms, and dietary changes provides further support for the notion that greater 
interdisciplinary management and holistic care is needed in renal units to improve patient 
quality of life.32 
To enhance the credibility of conclusions made in qualitative research, the collection 
of data from multiple sources regarding the same phenomenon is preferable (i.e. 
triangulation).55 Thus, future research should explore the perceptions and experiences of 
patients’ partners and family members who support them in adhering to the PD regimen and 
dietary requirements. The findings of the present study suggest that this may provide an 
understanding of the difficulties faced by patients’ partners due to changes in lifestyle and 
roles within the relationship. Qualitative research involving renal dieticians should also be 
conducted to explore their perceptions of patients’ GI health and experiences of providing 
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dietetic advice. This may reveal discrepancies between professional opinions and patient 
perceptions of GI health and symptom management, and thus identify opportunities for 
improved care. 
Finally, despite the large body of evidence indicating a high prevalence of 
psychological disorders in dialysis populations, as well as their co-occurrence with 
gastrointestinal dysfunction, no participants in the present study described significant 
psychological difficulties resulting from dialysis or associated symptoms. Whilst participants 
described negative emotions of frustration, anger, and disappointment, overall, they reported 
coping well with PD and its impacts. There are multiple possible explanations for these 
findings. First, there were challenges in recruiting patients who identified as being 
significantly burdened by poor health. Second, those in the study sample described being 
compliant with the PD therapy and had experienced relief from GI symptoms through various 
strategies, namely medications. Assessing patients of particularly poor health or those 
considered ‘non-compliant’ can be challenging52 and may therefore limit the transferability of 
the findings of this study to such groups. Furthermore, it is plausible to suggest that whilst GI 
symptoms are prevalent, patients consider other impacts of ESRD and renal replacement 
therapies to have graver consequences for their psychosocial wellbeing. Nevertheless, 
qualitative research aims to gain rich and in-depth rather than generalisable data. Future 
research should explore issues of GI health, diet, eating behaviour, and psychosocial 
wellbeing in other ESRD groups, for example, those receiving CAPD or HD. As these 
therapies involve different routines and procedures to APD, such patients may have unique 
psychosocial concerns to those of the participants in the present study. Given the evidence 
discussed, such research may be warranted particularly among patients with comorbidities 
such as diabetes, irritable bowel syndrome, depression, and anxiety. 
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Through qualitative methods, the present study had revealed themes describing the 
experiences and perceptions of patients undergoing APD regarding the psychosocial 
consequences of GI symptoms, the renal diet, and the dialysis regimen. The results suggest 
that patients experience losses of autonomy in multiple life domains as a result of these 
issues, and in response, attempt various medical, psychological, and behavioural solutions to 
regain autonomy and reformulate their experience. Furthermore, the findings highlight the 
breadth of psychosocial challenges faced by patients receiving dialysis that contribute to 
decrements in quality of life. They also emphasise the view that health care professionals 
should consider opportunities to promote patient autonomy and self-management, however, 
improved interdisciplinary care including psychosocial support may be required by some 
patients and their families. This is an important area of research to be pursued in future 
qualitative studies, with a view to explore the lived experiences of patients and thus inform 
interventions to improve quality of life. 
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Appendix A 
Article Published on the Kidney, Transplant and Diabetes Research Australia (KTDRA) 
Website 
Exploring the Psychological Impact of Dialysis    August 22, 2017  
Sadly when people living with end stage kidney disease begin to lose the complete function 
of their kidneys, there are only three avenues of treatment ahead of them. Some will be lucky 
enough to be able to have a successful kidney transplant, but others will need to maintain 
dialysis treatment for the rest of their life or choose a palliative pathway. 
Clinicians are acutely aware of the effect this dialysis process can have on the mental health 
of patients, who are not only coming to terms with their condition but also are dealing with 
the symptoms associated with it and the impact these have on their quality of life. 
In her second year of a Masters of Health Psychology at the University of Adelaide, Emily 
Duncanson with the support of the University’s Head of School of Psychology Professor 
Anna Chur-Hansen is working with patients to better understand the impacts of peritoneal 
dialysis on their quality of life. 
This research is a new collaboration between the Central Northern Adelaide Renal and 
Transplantation Service (CNARTS) and the School of Psychology at the University of 
Adelaide.  
“When someone is living with chronic kidney disease, their kidneys aren’t able to filter their 
blood and they need a dialysis machine to get rid of any waste, toxins and water for them,” 
Emily said. 
“My project is focused on the effect of a particular form of dialysis called peritoneal dialysis 
on patients living with end stage kidney disease.” 
There are two forms of peritoneal dialysis a patient can opt for, continuous ambulatory PD 
where they have four cycles of dialysis throughout their day or automated peritoneal dialysis 
where they are hooked up to the machine every night when they go to bed. 
Emily’s research is concerned with the gut (stomach and bowel) side effects of this dialysis 
treatment, which includes vomiting, indigestion and diarrhoea, and the impact this has on a 
patient’s mental health. 
GASTROINTESTINAL SYMPTOMS AND WELLBEING 68 
“There is fairly new evidence that suggests that gut health is linked to mental health. Patients 
who have kidney failure and are undergoing dialysis live with a range of symptoms and also 
have to change their diet and fluid intake.” 
“There is also evidence to suggest gastrointestinal problems are really prevalent in people on 
peritoneal dialysis, but there is little research exploring the patients’ experiences of living 
with those symptoms.” 
“I’ve conducted interviews with 10 patients to ask them what their experiences are in terms 
of treatment and how that impacts their psychological wellbeing and quality of life. I’m 
interested in the link between their gut health, their symptoms and their mental health to see 
if patients perceive there to be a connection there.” 
By understanding the link between gut health and a patient’s psychological state, Emily and 
Anna are hopeful the findings will inform future research aimed at improving outcomes for 
people living with end stage kidney disease. 
“We know that living with a chronic illness has all kinds of psychological impacts. The more 
we can understand the lived experience of these patients who are on a really intrusive 
treatment, the more we can work out interventions that can improve their quality of life, care 
and add to their life length,” Prof Chur-Hansen said. 
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Appendix B 
Presentation Slides of Final Results and Concept Map Presented at CNARTS Clinical 
Research Group Meeting 
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Appendix C 
Journal Article from American Journal of Kidney Diseases 
 
The following article56 has been included as an exemplar of the reference and 
formatting style of the American Journal of Kidney Diseases.  
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Information for Authors and Journal Policies 
American Journal of Kidney Diseases 
Editorial Office Contact Information 
Office E-mail: AJKD@med.upenn.edu 
Direct Line to Managing Editor Nijsje Dorman: +1 215-746-4467 
AJKD Editorial Office 
Centre for Clinical Epidemiology and Biostatistics 
Perelman School of Medicine at the University of Pennsylvania 
812 Blockley Hall 
423 Guardian Drive 
Philadelphia, PA 19104-6021 
The American Journal of Kidney Diseases, published monthly by Elsevier on behalf of the 
National Kidney Foundation, serves clinicians and scientists who treat and investigate kidney 
disease and associated conditions. AJKD is dedicated to providing high-quality, clinically 
relevant information in the form of original research articles, case reports, and a rich variety 
of educational features.  
ARTICLE TYPES 
Original Investigations 
Original Investigations evaluate pathogenesis, consequences, and treatment of kidney disease 
and hypertension, acid-base and electrolyte disorders, dialysis therapies, and kidney 
transplantation. Manuscripts must focus on clinical research; laboratory studies are suitable 
only if they are directly linked to measurements or outcomes in humans.  
An Original Investigation includes a structured abstract of up to 300 words and is limited to 
3,500 words (excluding abstract, references, acknowledgements, tables, and figure legends); 
most Original Investigations will have no more than 50 references and 8 figures/tables/boxes 
in total. The body of the manuscript is organized into Introduction, Methods, Results, and 
Discussion sections; the Introduction and Discussion should not include any subheadings. 
Criteria for review include validity, clinical importance, and interest. Reporting requirements 
vary by study design, which are listed in alphabetical order in this section. In all cases, use 
AJKD’s structured abstract headings, even if the reporting guideline recommends a different 
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format. If reporting company-sponsored research, consult the Good Publication Practice 
recommendations (GPP3). 
Case Series 
A retrospective description of the clinical course of 11 or more individuals or patients with a 
condition of interest. A case series typically focuses on the description of variations in 
clinical presentation and, unlike an observational study, does not pursue evaluation of 
research hypotheses. 
Clinical Trial 
An experimental study that assesses the effect of an intervention or compares the effects of 2 
or more interventions. AJKD requires registration in a public trials registry (see clinical trial 
registration policy). 
For randomized controlled trials, include a CONSORT flowchart to report participant flow 
through enrollment, allocation, follow-up, and analysis. Follow the CONSORT checklist 
matching the study design: 
• Trial With Parallel Group Design (more info) 
• Cluster-Randomized Trial 
• Noninferiority and Equivalence Trial 
• Pragmatic Trial 
• Trial of Herbal Medicine Intervention (more info) 
• Trial of Nonpharmacologic Treatment (more info) 
• Trial With Patient-Reported Outcomes 
• N-of-1 Trials (more info) 
Consider following the TIDieR checklist to describe the intervention. If appropriate, follow 
CONSORT’s checklist for reporting of harms. 
For nonrandomized trials evaluating behavioral and public health interventions, follow the 
TREND checklist. 
Decision Analysis or Cost-Effectiveness Analysis 
An analysis that weighs choices in clinical care by modeling the projected consequences of 
different strategies to identify the optimal choice and/or to inform clinical decision making or 
public policy. Follow the recommendations of the Second Panel on Cost Effectiveness in 
Health and Medicine (Sanders et al. JAMA. 2016;316[10]: 1093-1103) to report economic 
evaluations of health interventions. 
Diagnostic Test Study 
A study that compares the performance of 2 or more diagnostic tests or strategies. Follow the 
STARD checklist. 
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AJKD endorses the recommendations of the Consortium of Laboratory Medicine Journal 
Editors regarding methodological information to be included in studies using laboratory 
testing of biomarkers. 
Observational Study 
A study that observes and describes individuals or patients based on their exposure to a 
potential risk factor or an intervention with the purpose of assessing the validity of research 
hypotheses. In contrast to a trial, investigators do not deliver an intervention or manipulate its 
use; ie, they do not assign patients to treatment or control groups. Follow the STROBE 
checklist (more info) pertaining to the study design: 
• Cohort Study 
• Case-Control Study 
• Cross-sectional Study 
For genetic association studies, follow the STREGA checklist. 
Although no dedicated guidelines are available for reports from registries, AJKD also 
considers observational studies of this type. 
Prediction Study 
A study that describes the development or use of a model designed to estimate risk of 
reaching a specific clinical end point within a defined period of time. Prediction models may 
also be referred to as prognostic (or predictive) indices, rules, tools, or instruments. Follow 
the TRIPOD checklist (more info); for risk prediction models involving genetic risk factors, 
consult the GRIPS checklist (more info). 
Qualitative Study 
A study used to gain an understanding about people’s behaviors, attitudes, and values. 
Qualitative approaches include focus groups, in-depth or semi-structured interviews, 
observations, or document analysis. For qualitative research based on interviews and focus 
groups, follow the COREQ checklist. 
Quality Improvement Report 
A description of an activity that was conducted as an initiative to improve quality of care and 
that does not follow the design of a prospective research study such as a clinical trial or an 
observational study. Follow the SQUIRE checklist (more info). 
Systematic Review or Meta-analysis 
A systematic review follows an explicit protocol to systematically identify, appraise, and 
synthesize the findings of studies that address a similar question; a meta-analysis, which 
contains a quantitative synthesis of the results of the systematic review, is preferred, 
whenever possible.  
Include a PRISMA flow diagram to report study yield and selection (if relevant, adapt the 
format according to the specific reporting guidelines being followed).  
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For systematic review/meta-analysis of health care interventions, follow the PRISMA 
checklist (more info); for observational studies, follow the MOOSE checklist (Stroup et al, 
JAMA. 2000;283[15]:2008- 2012). 
For meta-analyses of gene-disease association studies, consult the Human Genome 
Epidemiology Network Review Handbook, Evangelou & Ioannidis (Meta-analysis methods 
for genome-wide association studies and beyond. Nat Rev Genet. 2013;14: 379-389), and 
Sagoo et al (Systematic reviews of genetic association studies. PLoS Med. 2009) for 
recommendations. 
For synthesis of primary qualitative studies (including by thematic synthesis, meta-
ethnography, and critical interpretive synthesis) report the approach for conducting the 
literature search and selection, appraisal, and synthesis of findings in accordance with the 
ENTREQ checklist.  
For systematic reviews and meta-analyses of individual participant data, follow the PRISMA-
IPD checklist. 
For network meta-analyses, follow the PRISMA network meta-analysis extension. 
Authors of systematic reviews are encouraged to prospectively register study protocols at the 
PROSPERO international registry, reporting the registration number in the Methods. 
Research Letters 
Research Letters report research findings relevant to clinical practice in a concise format 
comprising up to 800 words, 10 references, and a total of 2 figures or tables. Criteria for 
review include validity, clinical importance, and interest. Research Letters include an 
introduction, brief methods, key results, and a discussion, but no subheadings are used. 
Authors should use online supplementary material (combined into a single “Item S1”) for 
detailed methods or supporting data. Since reports of cases do not include methods, they are 
not suitable as Research Letters.  
Case Reports 
Case Reports provide a succinct presentation and discussion of a notable case or cases (up to 
10), and should have a single, well-defined message. Criteria for review include clinical 
importance, originality, and the clarity of the case presentation. These articles are limited to 
1,500 words and an unstructured abstract (up to 200 words) is required; most Case Reports 
will have no more than 20 references and 2 figures/tables/boxes in total. The format consists 
of an Introduction, Case Report, and Discussion. Authors should consult the CARE 
checklist for clinical case reporting, but since not all reports of cases fit naturally with these 
guidelines, discretion should be used in applying each item.  
Features 
AJKD features are designed to strengthen knowledge in the field of nephrology and help 
physicians provide their patients with the highest standard of care. Feature types for which ad 
hoc submissions are considered are described in this section.  
In a Few Words 
A nonfiction narrative essay which gives voice to the personal experiences and stories that 
define kidney disease. Submissions from physicians, allied health professionals, patients, or 
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family members are welcome, and may concern the personal, ethical, or policy implications 
of any aspect of kidney disease in adults and children. Details may be omitted to preserve 
patient confidentiality, but information should not be changed; the patient’s written 
permission will be needed if details are sufficient to recognize him/herself. References or 
footnotes are discouraged. Essays are limited to 1,500 words and up to 1 image. 
Narrative Review 
A review that covers a clinical, translational, or basic science topic of interest to practitioners. 
Narrative Reviews should describe the treatment, diagnosis or pathogenesis of a disease 
process or its complications, emphasizing recent advances in the field. Articles pertaining to 
basic science topics should give particular attention to cellular and molecular mechanisms of 
disease and their relation to diagnostic approaches or therapeutic applications. Criteria for 
review include clinical relevance, comprehensiveness, and balance. These articles are limited 
to 4,000 words; an unstructured abstract (up to 200 words) is required, and most Narrative 
Reviews will have no more than 100 references. The editors encourage the use of figures and 
tables (up to 8 total) to help convey the central concepts.  
Perspective 
An in-depth commentary on an issue of significance to the nephrology community. Criteria 
for review include originality, rigor of argument, and clinical relevance. Perspectives are 
limited to 3,000 words and 4 figures or tables; an unstructured abstract (up to 200 words) is 
required, and most Perspectives will have no more than 70 references.  
Policy Forum 
This feature will highlight current and emerging issues in nephrology that impact the clinical 
medicine in the United States and worldwide. The Policy Forum will discuss issues of 
payment policy, social policy, demographics, politics, and ethics, contextualizing these issues 
as they relate to the lives and practices of members of the kidney community, including 
providers, payers, and patients. Policy Forum articles are limited to 3,000 words and 4 figures 
or tables; an unstructured abstract (up to 200 words) is required, and most articles of this type 
will have no more than 50 references. 
Quiz 
An educational feature that recurs monthly and tests readers’ acumen in resolving a 
diagnostic or therapeutic dilemma. The first section includes a concise clinical history (200 
words or fewer), a maximum of 4 figures/tables, and 1 to 4 brief questions pertaining to the 
case. An answer to each question, further information regarding the clinical entity, and a brief 
statement of the final diagnosis are provided in a separate answer section, which may include 
an additional 2 to 4 figures and in most cases has no more than 400 words and 5 references. 
For initial submission, Quizzes should include a standard title page.  
Special Report 
An article summarizing the activities, perspectives, or findings of a group or initiative 
relevant to clinical practice or research in nephrology. Examples include position statements, 
reports of scientific workshops, and descriptions of the rationale or progress of initiatives or 
consortia. Criteria for review include the importance and clinical relevance of the issue 
addressed, timeliness of the topic, the appropriateness of the authors’ expertise and 
backgrounds for the scope of the article, and the novelty and anticipated impact of the 
conclusions. Articles of this type are limited to 4,000 words, and an unstructured abstract (up 
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to 200 words) is required; most Special Reports will have no more than 80 references and 8 
figures/tables/boxes in total.  
If a report of a conference, the article should make clear the motivation, participants, 
sponsors, and scope of the meeting, and should specify if the conclusions are endorsed as an 
official position of the sponsor. For such submissions, the review process will focus on 
making constructive suggestions for placing the report in context, rather than requesting 
changes to the recommendations/outcomes of the conference.  
Teaching Case 
A feature designed to educate readers regarding the diagnosis and/or treatment of a clinical 
problem. These articles focus on interpretation of pathology findings, laboratory tests, or 
imaging studies. Criteria for review include the clarity of case presentation, clinical 
applicability and interest, and educational value. Teaching Cases typically include an 
Introduction, a Case Presentation (with 4 suggested subsections: Clinical History and Initial 
Laboratory Data, Additional Investigations, Diagnosis, and Clinical Follow-up), and a 
Discussion. In general, each Teaching Case includes a table of laboratory data, relevant 
images, a box of key teaching points, and a summary of the authors’ approach to the clinical 
problem. These articles are limited to 2,000 words and require an unstructured abstract (up to 
200 words). Most Teaching Cases will have no more than 30 references and 4 
figures/tables/boxes in total. Although Teaching Cases are often invited, they may be 
submitted without invitation. 
OTHER CONTENT 
Letters to the Editor 
Letters must be in response to an article in AJKD and should not exceed 250 words (up to 5 
references and 1 figure or table may also be included) and 3 authors. Priority will be given to 
letters submitted within 4 weeks of the article’s date of online or print publication, whichever 
occurs first. 
Custom Features 
Certain content in AJKD is published by special arrangement only. The editors regularly 
invite editorials commenting on an article published in AJKD, or (for the In the 
Literature feature) that evaluate recent articles—typically in non–nephrology journals—that 
affect the nephrology community. Other custom features include clinical practice guidelines, 
commentaries on such guidelines, and reports of kidney disease surveillance data from 
private or public health agencies. 
SUBMISSION POLICIES 
Submission of a manuscript is understood to signify that the authors have complied with all 
policies in this document. Individuals who violate these policies are subject to editorial action 
including, but not limited to disclosure of violations to relevant entities (employers, funding 
agencies, etc) and/or the wider public via publication of an erratum, editorial, editorial 
expression of concern, or retraction. 
Originality 
Manuscripts are considered for publication if the article or its key features (1) are not under 
consideration elsewhere, (2) have not been published, and (3) will not appear in print or 
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online prior to publication in AJKD. This restriction does not apply to abstracts published in 
connection with scientific meetings; in addition, press reports arising from a conference will 
not be considered prior publication, provided that authors who discuss their work with 
reporters do not offer more detail than was contained in their oral or poster presentation. If 
copies of posters, slide sets, or audio/video recordings of presentations are produced in 
conjunction with a scientific conference, this is permissible as long as the materials are 
intended for meeting participants only.  
Any text, figure, table, or data from other sources must be clearly attributed. If copyright 
permission is required for any component of the submission, appropriate documentation must 
be on file before publication. To monitor compliance with the journal’s requirements 
regarding attribution, accepted manuscripts are screened using plagiarism detection software. 
Consistent with the position of the US Office of Research Integrity, AJKD does not consider 
“limited use of identical or nearly-identical phrases which describe a commonly used 
methodology or previous research” to meet the definition of plagiarism.  
Authorship 
In accordance with International Committee of Medical Journal Editors (ICMJE) 
recommendations, each author must meet all 4 of the following conditions; moreover, each 
person fulfilling these conditions must be listed as an author. 
(1) the individual made a substantial contribution to conception and design of the 
study, to data acquisition, or to data analysis and interpretation; and 
(2) the individual drafted the article and/or revised it for important intellectual content; 
and 
(3) the individual approved the final version of the submitted manuscript; and  
(4) the individual accepts accountability for the overall work by ensuring that questions 
pertaining to the accuracy or integrity of any portion of the work are appropriately 
investigated and resolved. 
If revision is requested, item 3 applies to any revised versions submitted to AJKD. Item 4 is 
intended to make clear that the responsibilities of authorship are not limited to direct 
accountability for the parts of the work that the author performed, but also cover knowing 
which co-authors are responsible for which other parts of the work, and having confidence in 
the accuracy and integrity of these co-authors. If questions arise about an aspect of a study or 
article, the authors have a collective responsibility to ensure the issue is resolved. 
Any individual who does not qualify as an author but who contributed to the work described 
in the manuscript must be named in the Acknowledgements. In particular, if medical 
writer(s)/editor(s) have been involved, their role must be explicitly acknowledged, and their 
affiliation/source of funding must be listed. 
For Original Investigations and Research Letters, a brief description of the contribution of 
each individual listed as an author must be provided in the Acknowledgements. (At their 
discretion, the editors may request this information for other article types.) 
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Potential Conflicts of Interest for Authors 
AJKD’s conflict of interest policies generally follow those of the ICMJE Recommendations. 
A conflict of interest exists for an author when s/he has financial or personal relationships 
with other persons or organizations that may inappropriately influence or bias his or her 
actions. There is a potential for a conflict of interest whether or not an individual believes that 
a relationship affects his or her scientific judgment. Conflicts can occur as the result of 
financial relationships, personal and family relationships, or academic competitive pressures. 
As described in the Support and Financial Disclosure Declaration section, authors must 
disclose all relationships that could be viewed as a potential conflict of interest. Editors may 
use information disclosed in conflict of interest statements as the basis for editorial decisions. 
Patient/Participant Protections 
All manuscripts reporting research studies involving human participants or data must include 
a statement that the research was approved by the appropriate research ethics committee (eg, 
an institutional review board), quoting the approval number. If the relevant ethics committee 
exempted the study from the need for approval, the name of the committee and a brief 
explanation must be provided. In all cases, the research must have been conducted according 
to principles having their origin in the Declaration of Helsinki. Studies related to 
transplantation must comply with the Declaration of Istanbul. 
Manuscripts reporting research studies must either state that written, informed consent was 
obtained from all participants or that the responsible ethics committee ruled that informed 
consent did not apply (eg, for a case series). If investigators have potential conflicts of 
interest, these must be disclosed to study participants, and a statement should be included in 
the manuscript to indicate that such disclosure was made. 
Manuscripts reporting quality improvement activities must include a statement that the plan 
for the quality improvement activity was approved by the clinical leadership of the 
organization whose experience is reported.  
Whenever possible, any information identifying individual patients or study participants 
should be avoided. If identifying information is necessary, the individual must be shown the 
manuscript and provide written informed consent before publication. 
Clinical Trial Registration 
To help limit publication bias and to aid in the identification of clinical trials for meta-
analyses, AJKD requires authors of manuscripts pertaining to clinical trials to register their 
study in a public trials registry. AJKD defines a clinical trial as any research project that 
prospectively assigns participants to an intervention (with or without a comparison group) to 
study the cause-and-effect relationship between a health-related intervention and a health 
outcome. Interventions include but are not restricted to drugs, biological products, surgical/ 
radiologic procedures, devices, behavioral treatments, process-of-care changes, and 
preventive care. This definition includes phase 1 to 4 studies. 
For trials that were completed before 2006, authors may, in lieu of registration, cite a 
published peer-reviewed article describing the study. Authors should provide a digital version 
of this article as a "Relevant Reprint" at the time of submission. If there is no previous 
publication, then the trial must be registered retroactively. 
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A list of other acceptable registries is maintained on the WHO Primary Registries page. 
Authors must include the minimum required information at the time of registration, and are 
encouraged to update the record with the full journal citation when the results are published.  
Research and Publication Integrity 
AJKD endorses the Singapore Statement on Research Integrity, which lists the 
responsibilities of researchers in upholding research integrity. AJKD considers irresponsible 
and unethical research practices to include fabrication (invention of data), falsification 
(tampering with data, including images), misrepresentation (plagiarism, duplicate 
publication, misattribution), or any other behavior that lessens the reliability or integrity of 
the research record. AJKD takes seriously its responsibility to respond to suspicions or 
allegations of misconduct according to its misconduct handling policy. 
For all research articles (Original Investigations and Research Letters), authors have a 
responsibility to report methodology accurately, clearly, and with sufficient detail such that 
the findings can be independently confirmed. Collectively, the authors are responsible that 
the article is an honest, accurate, and transparent account of the study being reported; that no 
important aspects of the study have been omitted; and that any discrepancies from the study 
as planned (and, if relevant, registered) have been explained. 
For all article types, the editors may at their discretion request to inspect raw data or 
unprocessed images. AJKD’s expectations regarding image processing are detailed in the 
Tables and Figures section. 
MANUSCRIPT PREPARATION GUIDANCE 
Title Page 
The title should be concise and descriptive. Reports of studies should not summarize the 
results in the title. For Original Investigations, a subtitle stating the study design is 
recommended. Other elements that should be included on the title page are: each author’s 
first and last names and highest degree(s); institution of each author; corresponding author’s 
contact information; word counts for the abstract (if present) and the body of the manuscript; 
and a short title (45 characters or fewer, including spaces) to be used as a running head (not 
necessary for Quizzes or correspondence). 
Note: The author list must comply with AJKD’s definition of authorship.  
Abstract 
Abstracts for Case Report, In Practice, Narrative Review, Perspective, Special Report, and 
Teaching Case manuscripts are unstructured and are limited to 200 words. Authors should 
provide a list of index words under the abstract. 
Original Investigations must include a brief (300 words or fewer) structured abstract followed 
by a list of index words. Formats for abstracts differ according to type of study, as shown in 
Table 1. 
The abstract headings listed in Table 1 may differ from published reporting guidelines; 
AJKD authors should follow the journal’s preferred headings. 
Table 1. Subheadings for structured abstracts of Original Investigations.  
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Manuscript Body 
Manuscripts must be double-spaced with numbered pages; use of 12-point Times New 
Roman and an unjustified right-hand margin is preferred.  
Word limits are provided in the Article Types section of this document. If following the 
recommended formats for reporting original research causes the manuscript to exceed the 
stated length limitation, the authors need not reduce the manuscript length before submission: 
if revision is requested, the editors will provide guidance on appropriate reductions or the use 
of supplementary online material. 
Acknowledgements 
Authors wishing to express thanks or note assistance should do so in the first paragraph of the 
Acknowledgements, which should be located after the manuscript text and before the 
reference list. In addition, any individuals who contributed to the work described in the 
manuscript but who do not qualify as authors must be named in this section. Authors are 
responsible for informing all those listed that they are being mentioned in the manuscript and 
for obtaining their approval prior to publication. 
Support 
This section must report any support for the work described in the submission, whether 
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directed to an author or that individual’s institution. Types of support include, but are not 
limited to: 
• grants, active or pending (including industry grants) 
• consulting fees or honoraria related to the study 
• funding of travel related to the study 
• fees related to data monitoring boards, statistical analysis, end point committees, etc 
• funds for writing or reviewing the manuscript 
• nonmonetary support (eg, writing or administrative assistance), or provision of 
medicines or equipment  
• employment 
Authors should specify whether or not the funders had any role in study design; collection, 
analysis, and interpretation of data; writing the report; and the decision to submit the report 
for publication. 
Financial Disclosure 
This section lists financial relationships with entities that did not support the study, but that 
might reasonably be considered to be relevant stakeholders. For manuscripts that discuss tests 
or treatments, relationships with entities offering alternatives to those tests or treatments are 
considered pertinent. The beneficiary may be an author or that individual’s institution, and 
the types of relationships include, but are not limited to:  
• patents (planned, pending, or issued) or royalties 
• employment or consultancy 
• board membership 
• payment or reimbursement of travel/accommodation expenses for expert testimony or 
lectures (including service on speakers’ bureaus) 
• stock/stock options 
The disclosure must cover the 36 months prior to submission of the manuscript, unless there 
are prior relationships that a reader could reasonably criticize an author for omitting (eg, 
long-term financial relationships that have now ended). A financial disclosure statement must 
be provided for each author; if no financial conflict of interest is identified, a statement such 
as “Drs X, Y, and Z declare that they have no relevant financial interests” must be included. 
In general, however, authors should disclose information even when there is a question as to 
whether a relationship constitutes a conflict. 
Other Disclosures 
If there are relevant nonfinancial associations (personal, professional, political, institutional, 
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religious, or other) that a reasonable reader would want to know about in relation to the 
submitted work, authors should include this information in the “Enter Comments” text box 
provided during the submission process. Authors should disclose information even when 
there is a question as to whether it constitutes a conflict. 
Contributions 
For Original Investigations and Research Letters, the Acknowledgements must contain a 
description of each author’s contributions and a statement of collective responsibility, eg: 
Contributions: research idea and study design: AB, CD, EFG; data acquisition: HIJ; 
data analysis/inter- pretation: AB, EFG; statistical analysis: KL; supervision or 
mentorship: EFG, MN. Each author contributed important intellectual content during 
manuscript drafting or revision and accepts accountability for the overall work by 
ensuring that questions pertaining to the accuracy or integrity of any portion of the 
work are appropriately investigated and resolved. 
Tables and Figures 
Tables and figures should be cited in numerical order in the text using Arabic numbering. 
Each table should be on a separate page of the manuscript file, ordered immediately after the 
references. The table number and title should be included above the table. Any additional 
information, including conversion factors for international units, should be included in notes 
below each table. 
Each figure should have a legend (figure title and other explanatory text); legends should be 
placed at the end of the manuscript file, after the references or tables (if present). Titles and 
legends should not appear in the figure files themselves. 
Figures should not be embedded within the manuscript file; instead they should be uploaded 
in the Editorial Manager system as separate files. For initial evaluation, figures must be of 
sufficient quality to be interpretable. If revision is requested, production-quality figures will 
be required, for which advice will be given. In general, authors should minimize conversions 
between file types. Resolution should not be reduced except in cases where file size would 
otherwise be impractically large; in most cases, pixel-based images should have a resolution 
of at least 1,200 dpi for graphs and flowcharts or 500 dpi for micrographs and other images. 
Color figures should use CMYK color mode. 
For all borrowed material, authors are responsible for applying for permission from the 
relevant publisher(s) for both print and electronic rights and are responsible for paying any 
permissions fees. In addition to providing proof of permission to the editorial office, authors 
must include appropriate wording in the figure legend or table note to indicate the source of 
the material.  
Photographs of identifiable persons must be accompanied by a signed release that indicates 
informed consent. 
AJKD’s expectations for image processing are that (1) adjusting contrast/levels or rescaling 
is acceptable if the adjustment was performed across the entire image; and (2) if certain parts 
of an image have been altered (other than obscuring confidential patient information), the 
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authors must explain what has been done in a text box provided during the submission 
process and must be prepared to provide the original image for the editors’ inspection. 
Supplementary Material 
When important supporting information for an article is too extensive for print publication 
(eg, a lengthy study questionnaire), it should be submitted as online-only supplementary 
material. Supplementary material should also be provided in lieu of stating “data not shown.” 
Supplementary material file(s) should be provided at the time of manuscript submission, and 
should be called out in the text (eg, Table S2, Fig S1, Item S4). A brief title for each piece of 
supplementary material should be provided in a section between the Acknowledgements and 
the References. Unlike standard figures, for supplementary figures, titles/ legends should be 
included in the file containing the supplementary figure. 
Online supplementary material is governed by the same copyright transfer policies as the 
article; if supplementary material has been reproduced from another source, the authors must 
provide documentation granting permission for its reuse in AJKD. 
Journal Style 
Provided the manuscript is clear and complete, editors will not penalize submissions that do 
not follow journal style. However, for publication, manuscripts must conform to journal 
style, and thus style changes may be requested at revision. 
Units of Measurement 
Values should be expressed in US conventional units; international equivalents or 
conversions are not necessary in running text. However, conversion factors should be 
provided in figure legends and table notes, as appropriate, eg, “Conversion factors for units: 
serum creatinine in mg/dL to μmol/L, ×88.4; urea nitrogen in mg/dL to mmol/L, ×0.357.”  
A list of values requiring unit conversions, as well as conversion factors, is available for 
download. 
Reporting P Values 
Numerical values should always be reported for P, even if they are nonsignificant. If the 
P value is greater than or equal to 0.9, it should be reported as 0.9, eg, 0.97 become 0.9. 
P values from 0.001 through 0.9 (inclusive) should be rounded to one nonzero digit, eg, 
0.0105 rounds to 0.01 and 0.0452 rounds to 0.05. P values less than 0.001 should be reported 
as <0.001, eg, 0.0009 and 1.92 x 10-6 become <0.001. 
Reference Style 
References should be compiled at the end of the manuscript according to the order of citation 
in the text, in the format shown in the following examples.  
Journal article (6 or fewer authors): 
Al-Absi A, Gosmanova EO, Wall BM. A clinical approach to the treatment of chronic 
hypernatremia. Am J Kidney Dis. 2012;560(6):1032-1038. 
Journal article (more than 6 authors): 
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Matsui S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum 
creatinine in Japan. Am J Kidney Dis. 2009;53(6):982-992. 
Journal article published online but not yet in print: 
Li Y, Kottgen A. Genetic investigations of kidney disease [published online ahead of 
print March 4, 2013]. Am J Kidney Dis. doi:10.1053/j.ajkd.2012.11.052. 
Supplement: 
National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice 
recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 
2006;47(5)(suppl 3):S1-S145. 
Item presented at a meeting but not yet published: 
Weiner D, Tighiouart H. Nutritional supplement use and mortality in dialysis. Poster 
presented at: Kidney Week 2012; October 30–November 4, 2012; San Diego, CA. 
Published meeting abstract: 
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Complete book: 
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Information attributed to a “personal communication” should be cited in-text. Prior to 
publication, the author must provide documentation showing that the individual cited has 
given permission to be named in the article as the source of this information. 
Where appropriate, authors are encouraged to cite underlying or relevant datasets. Data 
references should include the author name(s), dataset title, data repository, version (where 
available), year, and global persistent identifier. So that Elsevier can tag the reference 
properly, authors should add the text “[dataset]” immediately before the reference (this 
identifier will not appear in the published article). 
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MANUSCRIPT CONSIDERATION PROCESS 
All manuscripts are submitted and processed using the online manuscript handling system 
Editorial Manager (www.editorialmanager.com/ajkd).  
Unless the manuscript is out of scope or clearly inappropriate, two editors will review all 
submissions. If the editors deem that the manuscript is unlikely to be published in AJKD, it 
may be rejected at this stage. Otherwise, except for In a Few Words, Quizzes, Letters to the 
Editor and their Replies, and content published by special arrangement (KDOQI 
commentaries, etc), manuscripts will then undergo external review. Except in cases in which 
expedited handling is needed, Original Investigations, Research Letters, Case Reports, 
Narrative Reviews, Perspectives, Special Reports, and Quizzes are discussed at an editorial 
meeting before being invited for revision. Essentially all research articles will undergo 
statistics/methods review before being invited for revision; In addition, manuscripts with 
pathology or radiology content will generally be screened by individuals with appropriate 
expertise. 
Authors may provide editors with the names of persons they feel should not review their 
manuscript because of a potential conflict. However, when possible, authors should explain 
the reason(s) for their concerns. Editors will try to avoid selecting reviewers who have 
potential conflicts of interest, and will ask those who are invited to review to declare any 
relevant competing interests. Further information is available in the Potential Reviewer 
Conflicts and Review Policy sections.  
Manuscripts which have an author who is associated with the editorial team are handled by a 
separate workflow; information on the journal’s procedures for the treatment of such 
submissions is available in the Potential Editor Conflicts section. 
AFTER ACCEPTANCE 
Prepublication Embargo 
AJKD will not publish content that has already been published or disseminated. If the 
confidentiality of an AJKD article or its key elements is not maintained up to the point it is 
published by AJKD, the article’s acceptance for publication may be forfeited. The 
confidentiality restriction does not apply to information presented at scientific or clinical 
meetings, or publication of a conference abstract, provided that authors do not present or 
distribute the manuscript or its full findings. If copies of posters, slide sets, or audio/video 
recordings of presentations are produced in conjunction with a scientific conference, this is 
permissible as long as the materials are intended for meeting participants only. Press reports 
arising from a conference will not be considered prior publication, provided that authors who 
speak to reporters do not offer more detail about their work than was contained in the oral or 
poster presentation.  
If an author’s institution is interested in preparing a press release regarding the upcoming 
AJKD publication, the editorial office should be contacted for information regarding 
embargo dates. Authors may not discuss their accepted manuscript with reporters without the 
prior approval of the journal.  
In rare instances, such as an urgent public health need or testimony before a government 
body, authors may be permitted to discuss their unpublished AJKD article, even though it is 
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under embargo. Authors anticipating such a situation should contact the editorial office for 
approval before releasing any information contained in the article. 
Copyright 
AJKD offers authors the choice of subscription or open access publication. For subscription 
articles, Elsevier will contact the corresponding author by e-mail to request completion of a 
“Journal Publishing Agreement,” and the copyright will be assigned exclusively to the 
National Kidney Foundation, Inc., including the right to reproduce the article in all forms and 
media. Authors of open access articles retain copyright, and Elsevier will contact the 
corresponding author to request completion of an “Exclusive License Agreement.”  
Article Access 
In the subscription publishing option, articles are made available to subscribers as well as 
developing countries and patient groups through Elsevier’s access programs. 
In the open access publishing option, articles are freely available to both subscribers and the 
wider public, and may be reused according to the terms of the license; an open access 
publication fee is payable by authors or their funders. 
Open Access User Licenses 
All articles published open access will be immediately and permanently free for everyone to 
read and download. Permitted reuse is defined by the corresponding author’s choice of 
Creative Commons user license.  
The default license is the Creative Commons Attribution-NonCommercial-NoDerivs (CC 
BY-NC-ND) License, which, for noncommercial purposes, lets the article be distributed, 
copied, and included in collective works, as long as it is not altered and the authors are 
credited. 
In accordance with Elsevier’s agreements with funding bodies, corresponding authors may 
apply for the CC BY license if it is necessary to comply with their funding body’s policy; 
further information will be available from Elsevier once the open access publishing option 
has been selected.  
Open Access Publication Fee 
For each article published open access in AJKD, the authors or their research funders will be 
charged a publication fee. The fee excludes taxes and other potential author fees such as color 
and page charges. Information on agreements with funding bodies on the Elsevier website 
specifies the funding bodies that will prepay or reimburse publication fees. The standard 
publication fee is $3,000; however, if at least one of the article’s authors is a National Kidney 
Foundation member, a preferred rate of $2,400 applies. 
An author’s publication choice will have no effect on the peer-review process or acceptance 
of submitted articles. 
Compliance With NIH Public Access Policy 
If the corresponding author reports receipt of NIH funding when completing Elsevier’s 
Journal Publishing Agreement, Elsevier will send PubMed Central (PMC) the final peer-
reviewed manuscript as accepted for publication and will authorize that the article be posted 
for public access 12 months after final publication; authors will receive further 
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communications from the NIH regarding the manuscript. In accordance with AJKD's author 
agreement, authors should not post manuscripts directly to PMC. 
Proofreading 
Corresponding authors are provided with proofs via e-mail to check for typesetting and/or 
copy- editing errors. Important corrections to data presentation are allowed, but authors will 
be charged for excessive alterations to proofs. Corrections should be returned within 48 
hours. 
Page Charges 
For articles in excess of 2 journal pages, authors are responsible for paying a fee per page or 
partial page. If the first and last authors are both NKF members, the per-page charge is $50; 
otherwise, the per-page charge is $75. One journal page is approximately equivalent to 3.5 
double-spaced manuscript pages, 40 references, or 2 tables/figures. The editorial office will 
e-mail the corresponding author with an estimate of the page charges before typesetting; the 
invoice itself will be sent by the National Kidney Foundation after the article is published in 
print. If no response to the invoice or subsequent reminders is received, the editorial office 
will place a publication hold on all further papers from the corresponding author and all listed 
co-authors until the outstanding invoice is paid in full. Page charges and color reproduction 
costs are billed separately. 
Page charges are waived when the corresponding author for the manuscript is based in a 
Reasearch4Life Group A country; a 50% discount is available when the corresponding author 
for the manuscript is based in a Reasearch4Life Group B country (see 
www.research4life.org/eligibility/). 
Color Reproduction Charges 
With the exception of authors of Quizzes, authors desiring to have any or all figures printed 
in color are responsible for a $600 per-article color charge. After receiving a manuscript with 
at least 1 color figure, Elsevier will contact the corresponding author to ask whether color 
will be purchased. Provided that interpretability is not affected, the corresponding author may 
opt to have the color figure(s) appear in color online and in black and white in the print 
version of AJKD. Authors who choose color printing will be billed by Elsevier. Color 
reproduction costs and page charges are billed separately. 
Share Link and Reprints 
For articles not published open access, the corresponding author will, at no cost, receive a 
customized Share Link providing 50 days’ free access to the final published version of the 
article on ScienceDirect. This link can be used for sharing the article via any communication 
channel, including e-mail and social media.  
For an extra charge, the corresponding author may order paper offprints via the offprint order 
form, which is sent by Elsevier once the article is transmitted for copyediting and typesetting. 
In addition, any author may order offprints at any time via Elsevier's Webshop.  
Retained Author Rights 
Authors (or their employers or institutions) retain certain rights. For subscription articles, 
authors may use their articles for a wide range of scholarly, noncommercial purposes, 
provided there is no systematic or organized distribution of the published article. Permitted 
reuse of open access articles is determined by the author's choice of user license. 
   101 
OTHER EDITORIAL POLICIES 
AJKD policies generally follow those provided in the ICMJE Recommendations and the 
Committee on Publication Ethics (COPE) Code of Conduct for Journal Editors. 
Review Policy 
AJKD conducts single-blind review: authors’ identities are not masked to the reviewers, but 
reviewers’ identities are masked to the authors. With the exception of In a Few Words essays, 
the Acknowledgements of each published article will contain a statement summarizing the 
review process.  
If a manuscript is rejected, a copy is retained in the journal’s manuscript handling system for 
internal recordkeeping; the confidentiality of the files and associated records will be 
maintained unless requested otherwise by the authors or in exceptional circumstances 
involving suspected misconduct. 
AJKD endorses the COPE guidelines for ethical peer review. The manuscript must be kept 
confidential and the reviewer must request permission from the Editor beforehand if a 
colleague is to be consulted. Reviewers must not appropriate any information contained in 
the manuscript for their own work, nor should they contact the authors directly. Reviews 
should be kept confidential, even if the manuscript is later published. Comments should be 
constructive and professional. Reviewers should rate the manuscript, but should not state in 
the comments to the author whether the manuscript should be published. If a review does not 
meet these objectives, the editor may edit the reviewer's comments or may in extreme cases 
omit the comments from the material sent to the author. 
Author Appeal Policy 
Authors who believe that their manuscript was rejected due to a misunderstanding or mistake 
may e-mail the editorial office to explain why they believe the decision to be in error. 
Appeals must include substantive new information with direct bearing on the decision (eg, a 
well-reasoned argument providing compelling evidence that a key critique raised in the 
rejection letter relied on incorrect or outdated information). A difference of opinion as to the 
interest, novelty, or suitability of the manuscript for the journal is not sufficient reason for an 
appeal.  
The appeal will be considered by the EIC and other relevant editors. The journal’s response 
to the appeal will be final. Even if the journal agrees to reconsider the manuscript, acceptance 
is not guaranteed, and the reconsideration process may involve previous or new reviewers or 
editors and substantive revision. 
Conflict of Interest Policy 
AJKD’s conflict of interest policies generally follow those of the ICMJE Recommendations. 
A conflict of interest exists when an author, reviewer, or editor has financial or personal 
relationships with other persons or organizations that may inappropriately influence or bias 
his or her actions. There is a potential for a conflict of interest whether or not an individual 
believes that a relationship affects his or her scientific judgment. Conflicts can occur as the 
result of financial relationships, personal and family relationships, or academic competitive 
pressures. All participants in the peer review and publication process must disclose all 
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relationships that could be viewed as a potential conflict of interest. Editors may use 
information disclosed in conflict of interest statements as the basis for editorial decisions. 
Potential Author Conflicts 
The Support and Financial Disclosure Declaration section explains how authors must disclose 
the potential conflicts of interest. 
Potential Reviewer Conflicts 
Individuals who have potential conflicts of interest should not serve as peer reviewers. This 
includes individuals who work in the same institution as any of the authors (or will be joining 
that institution or are applying for a job there); who are or have been within the past 3 years 
mentors, mentees, close collaborators (in clinical care or research), or joint grant holders; 
and/or who have a close personal relationship with any of the authors. However, if the 
manuscript pertains to a large consortium to which a potential reviewer has contributed data 
but has not otherwise been involved, AJKD does not consider this to be a disqualifying 
condition. In addition, prior review of the manuscript for another journal does not necessarily 
disqualify an individual, provided that the reviewer considers the submission in its current 
form and according to AJKD’s article type criteria. 
Editors will try to avoid selecting reviewers who have potential conflicts of interest. Editors 
will also attempt to honor authors’ requests to exclude potential reviewers with conflicts of 
interest, provided that rigorous and comprehensive review is possible if these individuals are 
excluded.  
At the time they are invited to review, individuals must disclose any conflicts that could bias 
their opinions, and they must disqualify themselves from reviewing when appropriate. If a 
conflict of interest becomes apparent during the review process, the reviewer must contact 
the journal office and, when appropriate, ask to be recused. 
Potential Editor Conflicts 
Editors and editorial staff must not use information gained in the course of their duties for 
private gain. 
In addition, to manage potential editor conflicts, AJKD has customized handling procedures 
for Original Investigation, Research Letter, Case Report, Narrative Review, Perspective, 
Special Report, Core Curriculum, In Practice, Policy Forum, and Teaching Case manuscripts. 
In particular, if any editor who participates in editorial meeting discussions (Editor-in-Chief 
[EIC], Deputy Editor, Education Editor, Associate Editor, International Editor, Health Equity 
Editor) is an author of a manuscript, editorial staff select an Editorial Board Member to serve 
as Acting EIC. The Acting EIC must confirm that s/he has no conflicts of interest before 
beginning work on the manuscript. The Acting EIC may involve any unconflicted Feature 
Editor or Statistics/Methods Editor. The identity of the Acting EIC, reviewers, or any other 
individuals who were consulted will be kept confidential from all conflicted editors; however, 
if the manuscript is published, the name of the Acting EIC will be published with the article. 
If an editor who does not participate in editorial meeting discussions (Feature Editors, 
Statistics/Methods Editors) is an author on a submission, and it is not an article type the 
editor would ordinarily handle, it can be handled by the usual process. 
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 All AJKD editors (including Editorial Board Members asked to serve as Acting EICs) must 
recuse themselves from editorial responsibilities (and, if applicable, from the editorial 
meeting discussion of a manuscript) if they have a personal, intellectual, or financial 
involvement that potentially interferes with their ability to remain impartial. Potential 
conflicts of interest include: 
• close collaboration in clinical care or research with any author of a manuscript;  
• having a financial interest related to the subject matter of a manuscript;  
• or being a member of (or closely affiliated with) the same institution as one of the 
authors. 
If the EIC is recused, editorial staff will select an Associate Editor, International Editor, or 
Health Equity Editor without conflicts of interest to serve as Acting EIC. The identity of the 
Acting EIC and all others who are involved in the consideration process will be kept 
confidential; however, if the manuscript is accepted, the Acting EIC’s name will be published 
with the article. If no Associate Editor, International Editor, or Health Equity Editor is 
unconflicted, editorial office staff will select an Editorial Board Member to serve as the 
Acting EIC.  
Misconduct Handling Policy 
The AJKD editors recognize their role in making all reasonable efforts to maintain the 
integrity of the scholarly record, and will generally follow COPE recommendations when 
they suspect or receive credible allegations of a breach of journal policies. Any reports of 
potential misconduct submitted to the journal should include as much detailed information as 
possible to assist the editors in their investigation. Because of the time and resources required 
to thoroughly investigate allegations, AJKD must prioritize these activities on the basis of the 
most compelling evidence.  
In exceptional circumstances, the EIC may reach the conclusion that, in order to investigate 
possible misconduct, manuscript or review records must be shared confidentially with, for 
example, another journal office or with an author’s institution. In general, however, 
AJKD will first contact the author(s) to request an explanation concerning an allegation or 
suspicion of misconduct. 
When authors are unable to provide an explanation that the journal deems satisfactory, the 
authors are subject to editorial action including but not limited to contact with relevant 
institutions and/or regulatory bodies to disclose violations and/or request an investigation 
and/or publication of an editorial, editorial expression of concern, and/or retraction. 
The efforts of the editors in preventing, detecting, and responding to misconduct do not 
remove the responsibility of the authors for the validity of their work and publications. 
Complaint Policy 
As a member of COPE, AJKD seeks to follow the COPE Code of Conduct for Journal 
Editors. Authors, readers, reviewers, or members of the public who have a well-founded 
concern that the journal’s conduct deviates from the Code of Conduct should e-mail the EIC 
via the editorial office. Complainants who believe that the matter has not been satisfactorily 
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resolved may contact COPE by the process laid out in COPE’s complaints and 
concerns page.  
Advertising Policy 
Editorial independence is crucial to scholarly publishing, and the editorial team has full 
authority to decide on the content of the journal. The criteria for editorial decision making 
regarding journal content do not include any perceived effect on advertising revenue. The 
EIC has the right to review all new advertising that is proposed to be associated with the 
journal and may reject any advertising that he deems is not in keeping with the journal’s 
mission. 
Supplement Policy 
AJKD will consider publication of sponsored supplements that are of interest to its readers 
and demonstrate scientific validity. The content must be of sufficient informational value and 
quality to warrant a separate journal issue and must relate to a unifying theme. Submission of 
a supplement from a symposium or conference must occur in a timely fashion; in general, 
supplements will not be published if the publication date is more than 12 months after the 
date of the symposium or conference. No more than 2 supplements per month will be 
published. Publication costs must be borne entirely by the sponsor(s). Further information on 
sponsorship opportunities may be obtained from the publisher. 
Following initial contact with the publisher, a written proposal for a supplement to 
AJKD must be submitted to the EIC via the editorial office for consideration. The proposal 
must contain:  
• The Guest Editor's or Coordinator's name, affiliation, and contact information. 
• Topic(s) to be covered by the supplement, with a preliminary table of contents. 
• If the supplement is to be based on a conference or symposium, information on dates, 
venue, and financial supporter(s). 
• An estimate of the total number of double-spaced manuscript pages. 
• Sponsor(s) of the supplement. 
A Guest Editor is a subject expert who is responsible for the content of the supplement, 
ensuring the quality of each component manuscript and its contribution to a cohesive, 
coherent whole. The Guest Editor is responsible for ensuring that all manuscripts are in final 
form before submitting. The Guest Editor may elect to write an introduction or summary, but 
each article must include sufficient introduction and description of methods to stand on its 
own. In the absence of a Guest Editor, the authors are fully responsible for ensuring that the 
articles are consistent with one another and that their manuscripts are in final form before 
submitting. In such cases, a Coordinator is responsible for handling all submissions and 
facilitating communications between the authors and the editorial office. 
AJKD can provide the Guest Editor or Coordinator with information on the journal's 
production schedule, and can recommend deadlines for receipt of materials that are intended 
to allow enough time for review, revision, and reconsideration of the supplement 
manuscripts. It should be noted that any estimated publication date is simply a projection 
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based on the information available at the outset; whether it can be met will depend on receipt 
of the completed manuscripts at the AJKD editorial office in a timely fashion, the nature of 
the review required, and the extent of mandatory revisions. Ideally, a supplement based on a 
conference or symposium should be planned so that authors submit manuscripts to the Guest 
Editor or Coordinator at the time of the meeting. 
The manuscripts must be prepared and submitted according to standards governing regular 
journal content. Manuscripts that do not follow journal format will be returned for editing 
before review; furthermore, the editorial office will not begin processing the supplement 
articles until all of the manuscripts for the supplement are received. 
All supplements will undergo appropriate review of their contents. The review process 
depends on the number and length of articles and the nature of their content. Articles will 
almost invariably require revision; in addition, the EIC reserves the right to reject portions of 
the supplement, or the entire supplement. The editorial office will contact the Guest Editor or 
Coordinator regarding the decision to accept, reject, or require additional revisions. Once a 
supplement has been accepted it is formally scheduled for publication; changes to the 
publication date at this stage cannot be accommodated. 
The supplement must contain a statement indicating the source(s) of funding. It is the 
responsibility of the Guest Editor or Coordinator to disclose to the editorial office at the time 
of submission any restrictions or expectations communicated to the Guest Editor or 
Coordinator by the sponsor(s) regarding the contents of the supplement. Furthermore, the 
Guest Editor or Coordinator must state what, if any, financial relationship they may have 
with the sponsor of the supplement. Likewise, all authors should disclose what, if any, 
financial relationship they have with the sponsor of the supplement, or the manufacturer of 
any products, or competing products, that are discussed in their manuscripts. Each manuscript 
must indicate any support that was obtained for the manuscript or its contents. If medical 
writer(s)/editor(s) have been involved, their role must be explicitly acknowledged, and their 
affiliation/source of funding must be listed. Additionally, if the sponsor has a financial 
interest in a product either directly or indirectly discussed in the manuscript, this relationship 
should be identified, along with the name of the product. Information about sponsorship and 
related products will be published with each article in the supplement. 
Publication of a supplement does not constitute product or sponsor endorsement by the 
National Kidney Foundation or AJKD, and a disclaimer indicating this will be printed in each 
supplement. 
Articles published in a supplement of AJKD are subject to the same copyright restrictions 
that apply to articles published in regular journal issues. 
